Effects of C-type natriuretic peptide and endothelin-3 on the cGMP system in cultured rat C6 glioma cells. by Tung, Sin Yi Cindy. & Chinese University of Hong Kong Graduate School. Division of Biochemistry.
文'p 
/fk厂,k 弋. 
(ikf 終-^•書P SV;A 
P I ! 4 SEP IM J 
c^^ JBRARY ^ST^l/^y 
Effects of C-Type Natriuretic Peptide and 
Endothelin-3 on the cGMP system in cultured rat 
C6 glioma cells 
By 
TUNG SIN YI, CINDY 
• B.Sc. (Hons.), CUHK 
A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE 
REQUIREMENTS 
FOR 
THE DEGREE OF MASTER OF PHILOSOPHY IN BIOCHEMISTRY 
JULY 1994 
DEPARTMENT OF BIOCHEMISTRY 
THE CHINESE UNIVERSITY OF HONG KONG 
一 . 》
 一 .
 A , 
^
 ^ r /
 i
 f 6











I would like to express my most cordial gratitude to my supervisor 
Dr. David S. C. Tsang for his continuous guidance and support throughout 
my research study. His valuable advice and constructive criticisms have 
• granted me important enlightenment in my project. 
Many grateful thanks are given to my co-supervisors Drs. C. S. 
Cockram and Vincent T. F. Yeung in the Department of Medicine for their 
enthusiastic and stimulating discussion of my work. 
I would also like to thank my external examiner, Dr. Y. S. Chan, in 
the Department of Physiology, University of Hong Kong. I should also 
thank Drs. K. P. Fung, W. P. Fong and C. C. Wan for being members of my 
thesis committee. 
Heartful thanks also go to Dr. S. K. Kong and Dr. A. Stadlin for their 
valuable advice, and also to Mr. Stanley Ho, Mr. Leo Kwan, Miss W. C. Lee 
and Mr. K. W. Ho for their technical support. Also, I wish to thank all the 
staff and students in the Department of Biochemistry, especially Mr. Eric 
Leung, Miss Julia Tsang, Mr. K. F. Lau, Mr. Michael Leung and Miss S. L. 
Hung, for their vital help during my postgraduate study. 
My special thanks goes to my family and Mr. Stanley Poon for their 
constant support and encouragement during the past two years. 
This work was supported in part by a RGC grant awarded to Drs. C. S. 
Cockram and Vincent T. F. Yeung in the Department of Medicine and Dr. 
.David S. C. Tsang in the Department of Biochemistry, the Chinese 
University of Hong Kong. 
I 
— Abbreviations 
List of Abbreviations 
3 0 M G 3-0-methlyl-3[H]-gl ucose 
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AgO angiotensin I I 
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ETB endothelin receptor B 
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“ Abbreviations 
GC guanylate cyclase 
G F A P glial fibrillary acidic protein 
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GTP guanosine triphosphate 
H7 l-(5-isoquinoline sulfonyl)-2-methyl piperazine 
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PKA protein kinase A 
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P L A 2 phospholipase A2 
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S D M E M supplemented DMEM 
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ST staurosporine 
TCA trichloroacetic acid 
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一 — — — Abstract 
Abstract 
Peptide hormones CNP and ET-3, which are involved in the 
regulation of fluid and electrolyte metabolism in the periphery, 
are also found in the CNS. However, the mechanism of actions of 
these hormones in the CNS are still unclear though receptors for 
both peptides are found in astrocytes. The present study was to 
investigate the effects of CNP and ET-3 on cGMP production and 
other cellular metabolic processes on rat C6 glioma cells. The C6 
cells were employed as they are malignant and can be cultured 
easily to obtain a large number of cells. 
cGMP product ion in C6 glioma cells was markedly 
stimulated by lOnM CNP in time- and dose-dependent manners. 
This CNP-induced cGMP formation was inhibited by a brief pre-
exposure to ET-3 (100 nM). This effect of ET-3 appeared to be 
mediated by the PKC activating mechanism as PMA, a potent 
PKC activator, also inhibited the CNP-induced cGMP formation. 
However, as the effect of PMA was less potent than that of ET-3; 
besides, Ro 31-8220, a potent PKC inhibitor that antagonized the 
action of PMA, could only partially reverse the effect of ET-3, 
pathway(s) other than PKC activation might be involved. The 
PLA2 pathway, which is known to mediate some actions of ET-3, 
is a possible candidate but seemed not to be involved in this effect 
of ET-3 since arachidonic acid did not affect the CNP-induced 
cGMP formation. It appeared that CNP and ET-3 interacted to 
regulate the cGMP production in C6 cells while the inhibition of 
ET-3 on CNP-induced cGMP formation was mediated, as least in 
part, by PKC activation. 
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Apart f rom the cGMP formation, calcium transport was 
also affected by CNP and ET-3 but in different directions—CNP 
decreased whi le ET-3 increased calcium uptake in C6 cells. 
However, the combinations of these two peptides showed no 
significant change in calcium uptake. These suggested, besides 
cGMP formation, these two peptides also exerted their actions on 
calcium transport in C6 cells. 
Although CNP and ET-3 showed opposite actions in the 
above studies, only the addition of both peptides were found to 
increase cell volumes while neither peptides alone affected cell 
volumes. Thus, the changes of cGMP formation and calcium 
transport observed w i th these two peptides were not related to 
changes in cell volumes. Besides, these effects were not related to 
changes in the transport of taurine, an important osmolyte in 
astrocytes, as well as the transport of glucose, glutamate, tyrosine 
and leucine as the effects of CNP and ET-3 did not show any 
specific patterns. 
On the other hand, the stimulatory effects of ET-3 on DNA, 
RNA and protein synthesis in C6 cells were inhibited by CNP, 
although this peptide alone did not show any antimitogenic effect. 
This effect might be related to intracellular calcium concentration, 
as CNP inhibited while ET-3 stimulated calcium uptake. Also, the 
effects observed cannot be explained by changes in cGMP levels 
as exogenous cGMP could not reproduce the effect of CNP. 
V 
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In conclusion, this study revealed that ET-3 inhibited the 
CNP-induced cGMP formation in rat C6 glioma cells and this 
effect might be mediated, in part, by PKC activation. Besides, 
these two peptides affected calcium transport and cell 
proliferation in opposite directions similar to the actions of their 
respective analogs in the periphery. However, the present study 
d id not seem to support their roles in regulating f lu id and 
electrolytes balance in the CNS as both CNP and ET-3 by itself did 
not change the cell volumes of C6 cells. 
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Chapter 1 Introduction 
1.1 Astrocytes in the central nervous system (CNS) 
1.1.1 Characteristics of astrocytes 
The central nervous system (CNS) is consisted mainly of 
neurons and glia, and the latter is more numerous in all regions. 
The concept of neuroglia was first introduced by the German 
pathologist, Rudolf Virchow in 1856. The term "neuroglia" itself 
means "nerve glue", and was taken from the Greek. After the 
introduction of the silver-chromate staining method in 1873 by the 
Italian cytologist Camillo Golgi, a better understanding of the 
microscopic morphology of the glia was obtained and these 
findings provide an opportunity for studying the biochemistry of 
neuroglia, a distinct class of non-neuronal cells in the CNS 
(Young, 1991). 
Neurogl ia comprises three large families, astrocytes, 
oligodendrocytes and microglia. Astrocytes are the major 
constituents of the neuroglia and are 10 times more numerous 
than the neurons in the CNS (Guroff, 1980). Astrocytes are 
subdivided into fibrous and protoplasmic according to their 
morphologies at the light microscopic level and their localization 
to white or gray matter, respectively. Fibrous astrocytes have 
star-like morphology, wi th their cylindrical processes that branch 
infrequently, while protoplasmic astrocytes have thick and highly 




There are characteristic biochemical markers in astrocytes. 
For instance, astroglial intermediate filaments are composed of 
glial f ibr i l lary acidic protein (GFAP), a protein restricted to 
astrocytes in the CNS. Thus, a positive immunohistochemical 
reaction for GFAP has often been used as a major criterion for 
identifying astrocytes in both in vivo and in vitro studies (Eng et 
flZ., 1971; Smith et al； 1988; Grundt, 1988; Browning, 1988; Tardy 
et ah, 1991). Besides, molecular markers other than intermediate 
filaments have also been used as additional aids in defining 
astrocytes. For examples, the enzyme glutamine synthetase (GS) 
(Wu, 1963; Thorndike and Reif-Lehrer, 1971; Knox et al； 1971; 
Herzfeld, 1973; Waniewski and Martin, 1986) is highly enriched in 
astrocytes, and both fibrous and protoplasmic astrocytes are 
equally labelled by antibodies to GS (Norenberg and Martinez-
Heinandez, 1979). The calcium binding protein, S-100, and more 
recently the glutathione-S-transferase, subtype Yb, are useful 
markers for astrocytes (Boyes et al., 1986; Cammer et al” 1989). 
1.1.2 Functions of astrocytes 
1.1.2.1 General functions of astrocytes 
In the past, i t was believed that astrocytes served as passive 
physical support elements for the neurons. However, advances in 
methods for identifying and culturing astrocytes have made it 
possible to understand their function much better, it is now clear 
that astrocytes have key roles in normal brain function, in brain 
development and in the pathophysiology of the nervous system. 
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In normal physiology, astrocytes are considered first to play 
a critical role in the buffering of potassium. It is well-established 
that the balance and f low of K+ ions across the neuronal 
membrane is responsible for generating the action potential and 
convey of nerve impulse (Kimelberg and Norenberg, 1989). 
Therefore the level of potassium must be very finely regulated 
around the neurons, and astrocytes are thought to redistribute 
excess extracellular potassium from the brain through spatial 
buffering (Orkand et a\.t 1966). Second, astrocytes are important 
in the metabolism of glutamate and gamma-aminobutyric acid 
(GABA) wh ich are important excitatory and inhib i tory 
neurotransmitters, respectively (Kimelberg and Norenberg, 1989). 
In astrocytes, the glutamine formed by glutamine synthetase can 
serve as raw material for making more of the two transmitters 
(Waniewski and Mart in, 1986; Farinelli and Nicklas, 1992; 
Schousboe et aL, 1992). 
In brain development, astrocytes are known to have 
numerous important roles, such as influence on neuronal 
migration, guidance of axons and production of trophic factors. 
One of the well-known trophic factors produced is nerve growth 
factor (NGF) which affects neuronal development, differentiation 
and survival (Manthorpe et alf 1986; Cockram, 1990). In addition, 
astrocytes also produce or react wi th other peptides, for example, 
angiotensin which mediates central control of blood pressure, 
water dr ink ing behavior and release of pi tui tary peptides 
(Phillips, 1987); endothelins (Samson et alf 1991d) and the 
natriuretic peptides (Samson, 1988) which may exert central 
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contro l of f l u i d regulat ion and astrocyte mitogenesis 
(MacCumber et alf 1990; Levin and Frank, 1991). Another 
proposed function for the astrocyte is induction of the blood-brain 
barrier during brain development, which is formed by the highly 
impermeable tight junctions between capillary endothelial cells to 
impede the passive diffusion of water substances from the blood 
into the extracellular space of the CNS (Janzer and Raff, 1987; 
Tao-Cheng et alf 1987). 
In some cases of brain injury or in some neurological 
disorders, there, are changes in astrocytes that resulted in reactive 
gliosis by their hypertrophy and hyperplasia. Reactive astrocytes 
have more processes and increased metabolic activity, which then 
form glial scars at the injured sites (Lindsay, 1986). Besides, 
astrocytic swelling is usually seen as an early response to brain 
injury; such swelling may be a way to protect or rescue neurons 
during brain trauma (Kimelberg and Ransom, 1986). Astrocytes 
can survive such a traumatic insult because they can restore their 
normal osmolal i ty through volume regulation mechanisms 
(Kimelberg and Goderie, 1988; Kimelberg et al, 1992). 
1.1.2.2 Effects of neuroactive peptides on 
astrocytes 
The above observations suggest that astrocytes do respond 
to certain neuroactive substances. It is now known that astrocytes 
respond to three major groups of neuroactive molecules: amino 
acids, monoamines and peptides (Wilkin and Marriott, 1993). In 
addition, i t is now known that astrocytes express a variety of 
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receptors for peptides, which suggest that in some circumstances 
certain astrocytes might be the target of neuronally released 
peptides. For instance, the natriuretic peptides (NP), endothelins 
(ET) and angiotensinll (Agll) are peptides first found peripherally, 
are now found in the CNS, and they are believed to play 
important roles in the central regulation of fluid and electrolyte 
homeostasis (Sudoh et al, 1988; Yanagisawa and Masaki, 1989; 
Kumar et al., 1988). The receptors for these neuroactive peptides 
are detected on astrocytes in addition to neurons. In the case of 
NPs, more binding sites appear to be located on astrocytes than 
neurons. For Agl l , this neuroactive octapeptide is derived from 
angiotensinogen by the sequential actions of renin and Ag l 
converting enzyme. The components of this system have been 
found in both neurons and glial cells (Kumar et al” 1988). 
Comparisons of neuronal and astroglial cultures showed that 
both cell types possessed Ag l l receptors w i th similar KD and 
B m a x values (Summers et al., 1990). ETs, which were first 
reported to be synthesized by the endothelia in the periphery, are 
known to be produced by astrocytes in the CNS but not the 
endothelial cells of brain microvessels. These findings suggest that 
astrocytes appear to be the producer as well as target of ETs, and 
further suggest the autocrine and paracrine functions of ETs in 
the brain (Vigne et al" 1990; Marin et al” 1991). 
These peptides, following receptor binding, activate some 
known second messenger systems in astrocytes. For example, 
vasoactive intestinal peptide (VIP) has been shown to increase 
cyclic adenosine 3', 5' monophosphate (cAMP) levels in cultured 
astrocytes (Wilkin and Cholewinski, 1988), whereas vasopressin, 
5 
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A g l l and ETs stimulate the phosphoinositides (Pis) turnover 
(Murphy 1991; Zhang et alf 1990), and the NPs are the only family 
which has thus far been shown to increase cyclic guanosine 3' 5' 
monophosphate (cGMP) levels (Teoh et al" 1989). However, the 
effects after second messenger activation are still unclear, Also, 
whether interactions exist among various peptides in astrocytes 
remain to established. 
1.1.3 Gliomas and the rat C6 glioma cells 
The term glioma describes the group of glial neoplasms 
i n c l u d i n g ast rocytoma, g l iob lastoma, ependymoma, 
oligodendroglioma, and mixed gliomas such as oligoastrocytoma. 
Astrocytic gliomas, which contain fibrillar neoplastic cells, are the 
most common gliomas. 
A n important feature of astrocytic glioma tissue is cellular 
density. There are three different aspects of cellular density. The 
first is the greatest density attained by astrocytic gliomas called 
hypercellularity, because the cells are more crowded than normal 
or reactive astrocytes. 
Another aspect of cellular density is its regional distribution. 
Normal astrocytic cellular density in white matter is relatively 
constant. Even though the regional astrocytic cellular density 
varies in gray matter, which reflects the neuroanatomic 
arrangement of neurons and intermixed astrocytes, the variation 
is in a predictable pattern. In those cases where the astrocytic 
cellular density is increased such as in the state of gliosis, which is 
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a reactive rather than a neoplastic process, an even distribution of 
cellular density or a subtly increasing gradient of density is 
observed. However, gliomas are distinct in that the distribution of 
their cellular density fluctuates back and forth from higher to 
lower densities. This uneven cellular density probably reflects 
regionally variable proliferative capacity of glioma cells. Indices 
of cellular proliferation show marked variability in the percentage 
of proliferating cells in regions only a millimeter apart from one 
another. Moreover, regions of high proliferation show less glial 
differentiation, as determined by standard markers, such as 
GFAP, assay (McKeever and Chronwall, 1985). It is not clear 
whether the variation in densities is related to the action of 
growth factors and the presence of growth factor receptors in 
these cells. 
The third aspect of glioma cellular density applies to spacing 
of individual nuclei. In contrast to normal glia, astrocytic gliomas 
nuclei frequently touch and indent one another. Nuclear 
pleomorphism and hyperchromasia are characteristic features of 
gliomas. In cell cultures of gliomas that accentuate the borders of 
individual cells, the identification of high nuclear: cytoplasmic 
ratios characteristic of glioma cells is facilitated (McKeever, 
1993). 
Apart from the characteristics of gliomas described above, 
the understanding of gliomas is stil l rather scarce. However, 
malignant gliomas account for about one half of primary brain 
tumors, and the prognosis is poor wi th median survival times of 
about one year from diagnosis and only 20% survival at two years 
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(Cockram, 1990). Thus, there is a genuine need for new avenues of 
therapy, and so, at the present time, it seems important to gain a 
greater understanding of the biology, physiology and 
biochemistry of these tumors. 
The C6 glioma cell line has been studied extensively as a 
glial model for investigating glial cell properties and sensitivity of 
gl ial cells to various substances and conditions. The major 
advantages of using C6 cells are the rapid availability in large cell 
numbers necessary for experiments, and the homogeneous cell 
size distribution permitting the detection of even subtle changes in 
assay parameters. In addition, C6 cells express several glial— 
specific markers such as S100 (Pfeiffer et al.f 1970) and GFAP 
(Kempski, 1992), as wel l as enzyme markers such as GS 
(Vernadakis et al, 1992), transmitter uptake systems and ion 
carriers typical for astrocytes (Kempski et al., 1988). Levels of GS 
and GFAP expression are potentiated in the presence of dibutyryl 
cyclic adenosine 3',5f monophosphate (dbcAMP) and chronic (3-
receptor activation (Raju et al, 1980; Browning and Nicklas, 1982; 
Nicklas and Browning, 1983). C6 glia have been utilized as in vitro 
models of glial progenitor cells as it has been demonstrated that 
the early passage of C6 glioma cells are bipotential cells with glial 
progenitor properties (Vernadakis et al., 1992). In early passages, 
C6 cells exhibi t a h igh act iv i ty of cyclic nucleotide 
phosphohydrolase (cNP), an enzyme marker for oligodendrocytes 
(Poduslo and Norton, 1972; Poduslo, 1975), and a low activity of 
GS, an astrocytic enzyme marker, suggesting that C6 cells may 
behave like progenitor cells giving rise to both astrocytes and 
oligodendrocytes. However, w i th increasing cell passage, GS 
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increases and cNP decreases, indicating a shift to astrocytes in the 
late passages, whereas astrocytic enzymes, such as GS, increase 
greatly (Parker et al., 1980; Vernadakis et al., 1992). 
1.2 C-type natriuretic peptide (CNP) in the CNS 
The NPs are potent natriuretic, diuretic and vasorelaxant 
hormones. There is increasing evidence that many bioactive 
peptides first discovered iri the periphery are often found in the 
CNS. The NPs are among those peptides, and they are present in 
the brain together w i th their receptors. Among the three types of 
NPs, CNP is found in high concentrations in the CNS but not in 
peripheral tissues (Komatsu et al” 1991). It is therefore suspected 
that the NPs, especially CNP, may function as neuromodulators in 
the CNS. 
1.2.1 Structure and distribution of Natriuretic peptides in 
the CNS 
The natriuretic peptide system consists of three endogenous 
ligands, namely atrial natriuretic peptide (ANP), brain natriuretic 
peptide (BNP), and C-type natriuretic peptide (CNP). These 
peptides are found in the CNS and are synthesized by distinct 
genes but processed by similar proteolytic pathways (Fig. 1.1). 
ANPs that exist in the brain are N-terminally truncated forms, 
ANP (4-28) and ANP (5-28), of the major circulating form a-ANP 
(1-28) in rat, porcine and human (Shiono et al； 1986). BNP was 
first isolated from porcine brain and so named because of its 
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abundance in the brain compared wi th that of ANP. The primary 
structure of BNP varies considerably among species. Rat, human, 
procine' bovine BNPs consist of 45, 32, 26 and 35 amino acids (a.a.) 
residues, respectively, but w i th high degree of homology 
(Hashiguchi et al., 1988; Imura et al” 1992). CNP was originally 
isolated from porcine brain extracts (Sudoh et al； 1990). It has a 
primary structure, similar to a-ANP and BNP, consisting of 22 a.a, 
and another species which is a longer peptide called CNP-53 
(Minamino et al, 1991). Molecular cloning of the CNP precursor 
in porcine, rat and human has revealed that the primary structure 
of CNP-22 is highly conserved among these three species (Kojima 
et al” 1990; Komatsu et al； 1991; Tawaragi et al, 1990). This 
together w i th their wide and uneven distribution in the brain 
suggest that CNP could be an important neuromodulator in these 
species. Fig. 1.2 shows the structures of the three NPs existing in 
human. There are structural homologies among the three NPs. A l l 
of them comprise a 17-residues ring structure formed by an 
intramolecular disulfide linkage, which is characteristic of the NP 
family. However, CNP is structurally quite different from ANP 
and BNP in the N- and C-terminal sequences, especially at the C-
terminal where CNP ends at the second Cys residue and lacks 
further C-terminal extension from the ring structure (Sudoh et 
al., 1990; Jamison et al” 1992). This distinct structure of CNP may 
imply a different, perhaps a more specific role in the CNS than 




p r e - f o n n
 ^ 丨 1£5 丨 _ n g g f • z z z = i i i i i @ I 
1 1 1 
pro-form ^ ^ T 75 ^ “ 於畑 | 
mimm I . ^mmm^ 1 
I I j 
J ^ 108 I 
circulation 2 ！? :^严.!.:;;丨:1 I 
a-ANP m ^ l r-BNP „ ~ vr rj I 
system L_I 75 PJ.IA • BNP-32 ii;:jji=;|i;i;:il;j| I 
>i > • 
_ i ? ~ » I 
central a-AX\P[4-28J mm CNP-53 im^mmm：^ I 
nervous 肪 IM BNP-32 iliii^：：：^：：；!  n (03 I 
system a-ANPC5-28J _ CNP-22 國 I 
Fig. 1.1: Proteolytic processing pathways and endogenous 1 
molecular forms of three types of NPs in human CNS and 3 
circulatory system (N.D.: not detected in significant | 
concentration; a-ANP: ANP [1-28]; y-BNP: pro-BNP). | 
I . 1 1 I 
Introduction 
H O O C ^ © E ^ ^ ^ b o a ^ 
BNP-32 
C N P H 0 ° c \ x ^ 
Fig. 1.2: Structures and sequences of the three NPs in human 
2 4 
~~~ Introduction 
Although NPs are similar in their sequences, ANP, BNP and 
CNP are distr ibuted in discrete brain regions, and their 
distribution varies in different species. It has been shown that the 
highest concentration of ANP is localized in the hypothalamus and 
septum, followed by the midbrain, cerebral cortex, olfactory bulb, 
thalamus, pons/medulla oblongata, and hippocampus of rat brain 
(Nori i et al； 1985). On the other hand, BNP was barely detectable 
in rat brain, but intensely localized in the spinal cord (Saper et al" 
1989). However, in porcine brain, BNP concentrations were high 
in the caudate nucleus, medulla oblongata, lenticular nucleus, and 
olfactory bulb, being significantly different f rom those of ANP 
(Saper et al., 1989). Besides, the average concentration of BNP in 
porcine brain was higher than that of ANP (Sudoh et al, 1988; 
Imura et al, 1992). The distinct distribution of BNP from that of 
ANP, especially the higher concentrations of BNP in discrete brain 
regions, such as, central autonomic and endocrine control 
structures, together w i th its higher concentration in the brain, 
may indicate a broader neuromodulatory role for this peptide. 
The regional distribution of CNP in the rat brain differs from 
those of ANP and BNP; the CNP concentration is highest in the 
cerebellum, followed by the hypothalamus, thalamus, septum and 
olfactory bulb (Komatsu et al” 1991; Imura et al； 1992). There are 
species differences in the distribution of this peptide, e.g., the 
highest concentrations of CNP in human brain were found in the 
hypothalamus, followed by the midbrain and thalamus (Komatsu 
et al, 1991). In addition, it is important to note that CNP could be 
detected only in the brain of porcine, rat and human but not in 
peripheral tissues, including the heart (Kojima et al, 1990; Sudoh 
et al, 1990; Minamino et al； 1991). This suggests a unique role for 
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CNP in the CNS. In fact, recent molecular studies revealed that 
expression of the CNP gene is restricted to the CNS, which is 
different f rom those of ANP and BNP, where the latter two are 
found in extremely high concentrations in the heart and the 
periphery (Sagnella and MacGregor, 1990; Hirata et al, 1988). 
Moreover, CNP is present in higher concentration than ANP and 
BNP in human, porcine and rat brain (Minamino et al., 1991). At 
present, it is believed that CNP exerts its physiological functions 
mainly in the CNS as a neuromodulator in contrast to ANP and 
BNP which function mainly in the circulatory system (Minamino 
et al., 1991). Thus, CNP may be the more important of the three 
peptides wi th in the CNS in terms of neural functions. 
1.2.2 Actions of CNP 
The NP system seems to be involved in the regulation of 
water and salt intake, blood pressure, and secretion of 
vasopressin (AVP) in the direction of reducing body f luid and 
lowering blood pressure (Crandall and Gregg, 1986). Such actions 
of NPs are antagonistic to the central actions of Ag I I (Phillips, 
1987; Unger et al., 1988). This notion is supported by the fact that 
the distribution of ANP and Ag I I and their respective receptors in 
the CNS overlaps considerably (Quirion et al" 1981). It is believed 
that the central NP system and the renin-angiotensin system play 
important roles in the central control of cardiovascular and body 
fluid homeostasis but in opposite directions (Schultz et al, 1990; 
Shoji et al” 1987). The fact that CNP has the highest concentration 
among the NP's wi th in the CNS, wi th highly conserved sequence 
among species, and its distinct distribution in the CNS suggests its 
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importance in the central control of cardiovascular homeostasis. 
In addi t ion, the NP system may also be involved in 
neuroendocrine control and some other CNS functions, although 
the physiological significance of these actions is unclear at present 
(Imura et al., 1992). In view of the observations that both NP 
biosynthesis and actions are altered under pathological 
conditions, further investigations are required to elucidate the 
role played by the NP system in the pathophysiology of 
hypertension (Imada et al., 1985; Samson, 1988). 
1.2.3 Natriuretic peptide receptors and signal transduction 
in astrocytes 
The biological activities of the NPs are thought to be 
mediated by interaction w i th their receptors and followed by 
intracellular accumulation of cGMP through the activation of 
particulate guanylate cyclase (GC) (Jacobs et al” 1987; Chabrier et 
al., 1990; Furuya et al； 1990 Yeung et al., 1991a). Molecular 
cloning studies have identified three distinct types of NP receptors 
(Koller and Goeddel, 1992). Receptor A (ANPR-A) and receptor B 
(ANPR-B) are both transmembrane GC of approximately 120 -
140 kDa. The th i rd receptor, receptor C (ANPR-C), is a 
transmembrane protein of 60 -70 kDa wi th a short cytoplasmic 
tail and without the GC domain (Jamison et al., 1992; Chang et 
al., 1989). This receptor is also called the clearance receptor, which 
does not signal through activation of GC, but may function 
through intermediate G proteins to inhibit adenylate cyclase (AC) 
or activate the phosphoinositol pathway (Leitman and Murad, 
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1987; Fuller et al” 1988). ANPR-C imposes the fewest structural 
constraints of all the receptors on ligand recognition in a binding 
assay. ANP is the most potent hormone for stimulation of the 
ANPR-A GC; BNP is as effective, but only at approximately 
tenfold higher concentrations. The ANPR-B GC, on the other 
hand, produces only low amounts of cGMP after activation by 
relatively high concentrations of ANP or BNP. These suggest that 
either ANPR-B signals through a second messenger system other 
than cGMP or that the most potent ligand recognized by ANPR-B 
has not been described (Koller et al, 1991). The discovery of CNP 
helps to explain the signalling events upon ANPR-B binding (Fig. 
1.3). It was found that CNP did not increase intracellular cGMP 
through ANPR-A, but selectively activated the GC of ANPR-B at 
physiologically relevant concentrations and wi th a kinetic profile 
typical of a natural ligand (Koller et al, 1991). No other NP was 
able to stimulate substantially the GC of the ANPR-B, and the 
binding affinity of CNP to ANPR-B was 50- to 500-fold greater 
than the other human NPs (Koller et al" 1991). Besides, molecular 
studies showed that the ANPR-B was the major form of NP 
receptor present i n the CNS (Coussens et al” 1986). These, 
together w i th the f inding that the expression of the CNP gene 
was confined to the CNS and that CNP has the highest 
concentration among the three NPs in the brain, would strongly 
suggest that CNP, acting through ANPR-B, is responsible for 
most of the central effects attributed to NPs (Minamino et al, 
1991). However, l itt le is known about the physiological and 
binding characteristics of CNP and ANPR-B in the brain. 
2 4 
Introduction 
P E P T I D E S R E C E P T O R S 
A N F — — ( l 1 A 
X • j 
B N P • ( 〕 j O C 
Z 1 
C - t y p e N P 二 c ) l ( \ ~ ) B 
• Kinase Homology Quanylyl Cyclase 
• Domain Domain 
EXTRACELLULAR j INTRACELLULAR 
Fig. 1.3: Human natriuretic peptide receptors. Receptor A = 
ANPR-A, receptor B = ANPR-B, and receptor C = ANPR-C. The 
peptide affinity is indicated by the arrows wi th the solid lines. The 
arrow wi th the dashed line indicates that BNP also binds ANPR-
A, but w i th a lower affinity than ANP. The extracellular domains 
of the three receptors have structural similarities. In contrast, 
while ANPR-A and ANPR-B have protein kinase and guanylyl 
cyclase domains, ANPR-C has a very short cytoplasmic domain 
without kinase or guanylyl cyclase sequences. 
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ANPR-B were found to distr ibute main ly in the 
circumventricular organs, such as the subfornical organ, area 
postrema, and organ vasculosum lamina terminalis (OVLT), and 
the olfactory bulb, while moderate levels of binding sites were 
seen in hypothalamic nuclei and the brain stem structures (Imura 
e t a l ” !992). Besides, both ANPR-A and ANPR-B were detected in 
the cerebellum, but only ANPR-C was found in the cerebral cortex 
(Imura et al,, 1992). Moreover, ANP- receptors are localized not 
only on neuronal cells but also on glial cells, and the existence of 
binding sites that respond to ANP, BNP and CNP, as monitored by 
cGMP generation, was also demonstrated in cultured astrocytes 
(Yeung et al., 1991b,1992a; Ngai et al, 1992). However, the 
physiological significance of ANP receptors, and the role of cGMP 
generated upon binding in astrocytes remain unclear. Recently, it 
has been demonstrated that exposure of PC12 rat 
pheochromocytoma cell cultures (a neural cell line) to ANP 
resulted in hyperpolarization, which is accompanied by a 
significant leakage of cGMP into the culture medium (Fiscus et 
al., 1987). This suggests that the cGMP generated could enhance 
membrane excitability and spontaneous action potentials. These 
may imply that the NP-induced cGMP production in astrocytes 
could interact w i t h neurons and have an important role in 
modulating neuronal function. 
1.3 Endothelin-3 (ET-3) in the CNS 
1.3.1 Structure and distribution of endothelins in CNS 
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Endothelin (ET), a potent 21 amino acid vasoconstrictor 
peptide, was originally isolated from porcine aortic endothelial 
cells, and acts as a local hormone in the cardiovascular system 
(Yanagisawa et al., 1988b). The ET family includes three 
physiologically active peptides (endothelin 1, ET-1; endothelin-2, 
ET-2; and endothelin 3, ET-3) that differ from each other by a few 
amino acids (Yanagisawa et al, 1988a). Fig. 1.4 shows the 
structures and sequences of the three isoforms of ETs. ET-1 is the 
only ET to be made by endothelial cells (Yoshimoto et al., 1991), 
while the origin of ET-2 is stil l unclear. However, ET-3 is the 
predominent ET i n the brain, and this suggests the 
neuromodulator role of ET-3 and that i t participate in 
neuroendocrine regulation in addition to its cardiovascular action 
in the periphery (Ehrenreich et al., 1991; Samson et al, 1991b; 
Yamashita et al” 1991). Like many other biologically active 
peptides, ET is produced from a prepropeptide. The production of 
the active peptide involves the formation of a 38-, 37- and 41-
residue (for ET-1, ET-2 and ET-3 respectively) "big endothelin" or 
proendothelin (Fig. 1.5), fol lowed by a proteolytic cleavage 
between Trp and Val residues by the ET converting enzyme which 
yields the bioactive peptide. There are distinct genes encoding the 
three peptides but the proteolytic processes for the three are 
similar, and the typical processing pathway is shown in Fig. 1.6 
(Anggard et al., 1990). 
ETs are widely distributed in the CNS and are produced by 
both neurons and astrocytes, the latter being a more important 
synthetic site (MacCumber et al., 1990; Ehrenreich et al., 1991). 
Unlike astrocytes and peripheral endothelia, endothelial Fig. 1.4 
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Fig. 1.4: Structures and sequences of the three isoforms of ETs 
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Fig. 1.5: Structures and sequences of the three isoforms of the 
proendothelins or big endothelins 
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yield bioactive endothelin (ET-1 as example) 
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cells f rom brain microvessels did not produce ETs (Vigne et al., 
1990). Primary cultures of rat hypothalamic cells release 
measurable amounts of ET-1, ET-2 and ET-3 into the culture 
medium (Krsmanovic et al., 1991). Within the hypothalamus, ET-
l ike immunoreact iv i ty is present in paraventricular and 
supraoptic neurons w i th terminals projected to the posterior 
pituitary gland (Yoshizawa et al, 1990). Immunoreactive ETs are 
also present in the anterior lobe of the pituitary gland (Samson et 
al” 1991c; Stojilkovic et al, 1990, 1991). 
1.3.2 Actions of ET-3 
ETs were init ially thought to be involved primarily in the 
control of cardiovascular functions wi th potent vasoconstrictor 
properties, but the presence of ET receptors and its actions in a 
wide variety of tissues other than blood vessels suggested a much 
broader spectrum of functions (Sakurai et al., 1992). Recently, the 
discovery of ETs in the brain, especially where ET-3 is the 
predominant form. This together wi th the finding of the presence 
of its specific receptors in the CNS suggested that these peptides 
participate in neuroendocrine regulation (Sakurai et al., 1992). 
A t least two functions have been proposed for ETs. In the 
first mode, ETs could be a signalling molecule maintaining 
cardiovascular homeostasis under healthy conditions, like other 
vasoactive hormone, such as A VP, angiotensins and NPs. Along 
this line, it has been suggested that ET could be involved in long-
term (hours to days) regulation of endocrine function (Anggard et 
ah, 1990). In this aspect, it was found that ET triggered secretory 
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responses in hypothalamic and pituitary cells. For instance, ETs 
have been shown to promote the release of A VP wi th substance P 
f rom hypothalamic slices (Calvo et al, 1990), and the release of 
gonadot rop in releasing factor (GnRH) f rom perfused 
hypothalamic neurons and cultured GnRH neuronal cell 
(Krsmanovic et al, 1991). ET has been shown to be involved in the 
control of A VP and oxytocin release from the posterior pituitary 
(Yoshizawa et al； 1990; Samson et al, 1991b), and to stimulate the 
release of luteinizing hormone (LH), follical stimulating hormone 
(FSH), thyro id st imulating hormone (TSH), prolactin (PRL), 
growth hormone (GH), and substance P from anterior pituitary 
cells (Calvo et al； 1990; Yoshizawa et al, 1990; Stojikovic et alf 
1991; Samson et al； 1991b,c). 
The other proposed mode of action is related to defense and 
repair. In this aspect, ET has been shown to be produced locally in 
emergencies or in defensive events, such as lesion or wound 
repair. Here, the mitogenic effect of ETs is believed to play an 
important role in cellular responses to injury (MacCumber et al., 
1990; Yada et al., 1991). In addition, ET production was observed 
in hippocampal astrocytes at a lesion site (Koyama et al., 1993 ). It 
is believed that ETs may participate in the control of the reactivity 
of astrocytes to injury, in part, by their proliferative effect on 
astrocytes by causing and/or enhancing active gliosis. Thus, the 
mitogenic effect of ETs in astroglia may mediate responses to 
neuronal injury by promoting the wound healing processes 
(MacCumber et al” 1990). 
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1.3.3 ET receptors and signal transduction in astrocytes 
The s t ruc tura l differences of ETs, their b ind ing 
characteristics and physiological actions suggest the existence of 
different ET receptor subtypes. Recently, two distinct receptor 
subtypes, ETA(73kD) (Mart in et al, 1990) and ETB (47kD) 
(Sakurai et al； 1990), have been characterized by molecular 
cloning. Both are members of the G protein-coupled family of 
rhodopsin-type receptors (Sakurai et al” 1990). ETA receptors 
have higher affinity for ET-1 and ET-2 than for ET-3, while ETB 
receptors do not discriminate between the three ETs. 
In the CNS, ET was produced by nervous tissues and binds 
w i th high affinity to receptors in brain tissues. Both ETA and ETB 
receptors are expressed in the brain, but no detailed 
characterization of the receptor subtypes has been performed 
(Martin et al., 1990). Abundant ET-binding sites were detected in 
the hypothalamic nuclei, the anterior hypothalamic area and 
adenohypophysis, the hippocampus, the cerebellum and the 
choroid plexus (Stojilkovic et al., 1992; Goldman et al., 1991). 
Specific b inding of ET has also been demonstrated in cultured 
hypothalamic cells, GnRH neuronal cell lines and anterior 
p i tu i tary cells. A t present, l i t t le is known about the local 
distr ibution of ET receptors in the CNS. In the cerebellum, ET 
receptors are found and ET is produced by astrocytes (Mac 
Cumber et al, 1990; Ehrenreich et al., 1990); also, these cells are 
subject to selective autoregulation, as demonstrated by the 
potentiation of ET-1 secretion after activation of glial cell ET 
receptors, which also implies the autocrine function of ET. On the 
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other hand, cerebellar neurons possess specific ET receptors but 
are probably responsive to ET produced by neighboring glial cells 
(Stojikovic and Catt, 1992). 
Although ETA and ETB receptors are distinguishable both in 
pharmacological and molecular terms, both receptor subtypes 
belong to the family of Ca 2 + -mobi l iz ing receptors that are 
coupled to phospholipase C (PLC) via a regulatory G protein (Fig. 
1.7) (Sakurai et al, 1990; Lin et al, 1991). Thus, activation of these 
receptors is associated w i th increased PI hydrolysis, which 
produces the two second messengers, inositol 1,4,5-trisphosphate 
[I(1,4,5)P3 or IP3] and diacylglycerol (DAG), and a concomitant 
rise in intracellular calcium level. 
In the CNS, stimulation of PI breakdown appears to be a 
general response to the activation of ET receptors in astrocytes 
(MacCumber et al” 1990) and neurons (Zhang et al., 1990). In 
p i tu i tary cells, ETs stimulate the production of IP3 and its 
metabolites, including I(1,3,4,5)P4 and its breakdown products, 
1(1,3,4)P3 (Stoji lkovic et al” 1992). On the other hand, the 
intracellular increase in DAG leads to the stimulation of protein 
kinase C ( PKC) which is believed to be involved in the mitogenic 
effect of ETs (MacCumber et al., 1990). 
Besides activation of PLC, it is found that ET receptors are 
coupled to the act ivat ion of another phospholipase, 
phospholipase A2 ( P L A 2 ) in some cell types (Fig. 1.7) (Simonson 
and Dunn, 1990; Masaki, 1991). The PLA2 activation by ET is 
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found to potentiate AVP release from the neurohypophysis (Ritz et 
al” 1992). 
As mentioned above, ET-3 has been suggested to be the 
predominent form present in the nervous system (Yanagisawa 
and Masaki, 1989). Studies on the actions of ET-3 in neuron and 
astrocyte cultures showed that ET-3 had little effects on calcium 
mobilization in neurons, while it produced a robust intracellular 
Ca2+ increase in astrocytes (Goldman et al" 1991). The functional 
implications of the sustained rise in Ca2 + in astrocytes by ET is 
unclear at present. However, as the morphology of the astrocytic 
processes is partly controlled by intracellular Ca2+ levels, ET 
released by neurons or astrocytes may affect the morphology of 
astrocytes (MacVicar, 1987). 
Moreover, as sustained elevation is shown to be 
mitogenic for astrocytes (MacCumber et al., 1990; Supattapone et 
al., 1989), this may be the signal for astrocytes to undergo cell 
division in response to brain injury. ET immunoreactivity was 
found to increase in astrocytes fol lowing excitotoxic lesions 
(Koyama et al., 1993). So ET may be involved in the immune 
response and the repair of lesion sites during brain injuries. 
1.4 cGMP second messenger system in astrocytes 
1.4.1 Second messenger systems in astrocytes 
Cultured astrocytes are capable of receptor—coupled 
synthesis of cAMP, cGMP, inositol phosphates (IPs)/and the 
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movement of calcium from intracellular stores and across the 
plasma membrane (Kimmelberg, 1988). In short, astrocytes in 
v l t r o express most elements of the second messenger systems like 
astrocytes in situ (Hosli and Hosli, 1991; Wilkin et al； 1992). 
The concept of cAMP as an intracellular second messenger 
of hormones is first developed by Sutherland and co-workers 
(Robinson et al” 1971). Intracellular cAMP formation is stimulated 
upon G protein coupled AC activation. The AC has been purified, 
cloned and sequenced (Krupinski et al” 1989), and has also been 
local ized i n astrocytes (Ariano et al" 1982). The major 
intracellular receptor for cAMP is the cAMP-dependent protein 
kinase, or protein kinase A (PKA), which mediates protein 
phosphorylation and play a role in the modulation of the cell cycle, 
proliferation and differentiation (Beebe and Corbin, 1986). 
Another second messenger system in the astrocytes is 
related to the PI hydrolysis, which is induced by PLC activation. 
The PI second messenger system comprises two major elements— 
the IPs that cause calcium mobilization; the DAG. that activates 
PKC to phosphorylate its substrates (Simonson and Dunn, 1990; 
Taylor, 1990). It is found that the intracellular Ca 2 + rise could 
trigger cell activation in many cell types, including astrocytes, 
which is involved in diverse cellular processes, such as secretion, 
cell division, metabolism and membrane permeability through 
interactions w i th the Ca2+-binding proteins that activate specific 
protein kinases (Stull et al., 1986; Campbell, 1987). There are 
different kinds of Ca2+-binding proteins, but the most important 
and unique one is calmodulin because i t is found in most 
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eukaryotic cells. Calmodulin mediates Ca2+ control of a large 
number of enzymes which play important roles in Ca2+-
dependent cellular processes (Stull et al； 1986). On the other 
hand, the PKC that is activated by DAG in the presence of Ca2+ is 
related to the control of cellular functions and proliferation in 
astrocytes (Kikkawa and Nishizuka, 1986). In the brain, there are 
at least seven subspecies of PKC, one of which is expressed only in 
the CNS, and all these PKC subspecies show subtle differences in 
their mode of activation, sensitivity to Ca2+ , and catalytic activity 
toward endogenous substrates (Kikkawa et al., 1989). The 
presence of PKC in astroglia of brain sections was demonstrated 
immunocytochemica l ly (Mochly-Rosen et al., 1987), and 
astrocytes have also been stained wi th antibodies against PKC . 
In addit ion to PLC, another phospholipase, PLA2, is also 
found in the astrocytes (Huang, 1989). Receptor-mediated 
activation of PLA2 appears to be coupled to G proteins. PLA2 
catalyses the hydro lys is of phosphol ip ids to release 
lysophospholipid and free fatty acid, usually arachidonic acid. 
Arachidonic acid is released by direct cleavage of PLA2 at the sn-2 
position of the glycerophospholipid molecule. Once arachidonic 
acid is cleaved, i t is metabolized via the lipoxygenase or 
cyclooxygenase pathway to produce hydroxylated products or is 
rapidly reacylated into complex lipids. Arachidonic acid and its 
oxygenated metabolites (e.g. prostaglandins) are believed to play 
a pivotal role in the regulation of cellular responses in astrocytes 
(Chilton, 1991). 
1.4.2 cGMP as second messenger in astrocytes 
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Although cGMP was first found to be present in cells in 1963, 
its potentially significant actions in cellular systems, such as 
coupling the photoreceptor and relaxing smooth muscle were not 
described unt i l the 1980's (Lincoln and Cornwell, 1993). cGMP is 
now recognised as an important intracellular mediator of 
extracellular signals, such as nitric oxide and NPs, in the CNS. 
cGMP is synthesized by GC which uses guanosine 
triphosphate (GTP) as the substrate. There are two forms of GC 
in the astrocytes, the membrane-bound and the soluble forms. 
Both forms of GC and cGMP have been localized in astrocytes in 
brain sections (Zwiller et al” 1981). Current evidence suggests that 
these two different forms of GC are activated by different 
mechanisms; whereas the membrane-bound enzyme is activated 
by the NPs, i t appears that the soluble form is activated by nitric 
oxide (Wilkin and Marriott, 1993). 
In astrocytes, i t appears that NPs are the only class of 
peptides that has receptors that contain or couple to GC. A l l 
members of NPs can activate the membrane-bound form of GC; a 
comparison of the relative potencies of these peptides on cGMP 
metabolism suggests that each peptide probably interacts wi th 
different receptor (Yeung et al., 1991b, 1992a). 
1.4.3 Post cGMP cascade effects 
cGMP interacts w i th three types of intracellular proteins: 
cGMP-dependent protein kinases, cGMP-regulated ion channels, 
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and cGMP-regulated cyclic nucleotide phosphodiesterases (PDEs) 
(Lincoln and Cornwell, 1993). This indicates that cGMP has a 
wide spectrum of effects in different cell types. For example, 
cGMP may stimulate, inhibit or have no effect on protein 
phosphorylation (Lincoln and Cornwell, 1993). 
A m o n g the various cGMP-dependent intracel lular 
messengers, the cGMP-dependent protein kinases are well-
studied. The cGMP-dependent protein kinases are found in 
different cell types, and one of the effects of these kinases is the 
stimulation of a Ca2 + -pumping ATPase in smooth muscle cells 
which causes the lowering of intracellular calcium level (Sarcevic 
et al., 1989). The cGMP-regulated ion channels are well-known in 
vertebrate photoreceptors. Application of cGMP to retina rod out 
segments was found to produce a rapid, transient depolarization 
of the membrane due to the influx of Na+ and Ca2+ ions into the 
cell, suggesting that cGMP activated a cation channel 
(Muller/1983). In the case of cGMP-binding PDEs, cGMP acts as 
an allosteric effector to stimulate, or to inhibit the specific PDE 
activity. In most cases, the cGMP-stimulated PDE (cGS-PDE) 
catalyses the hydrolysis of intracellular cAMP, which suggests 
that cGMP regulates cAMP-dependent signal transduction 
process by decreasing protein phosphorylation (Lincoln and 
Cornwel l , 1993). However, the cGMP receptor protein(s) 
employed in astrocytes are still unknown. 
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1.5 The aims of this project 
NPs and ETs are hormones involved in the regulation of 
body fluid and electrolyte homeostasis. They are responsible in the 
regulation of blood pressure and renal function (Huot et al., 1991; 
Anggard et al, 1990). However, these two peptides act in the 
opposite directions. For example, NP has potent vasodilatory 
effect whi le ET is vasoconstrictive on vascular smooth muscle 
cells and glomerular mesangial cells (Marin-Grez et al, 1986; 
Yanagisawa et al, 1988b; Badr et al； 1989; Kohno et alr 1993). In 
addition, both NP and ET, and their specific binding sites are 
found in the CNS, especially in the astrocytes (Yeung et al, 1991b, 
1992a; MacCumber et al, 1990). The predominant isoforms of NP 
and ET in the CNS are CNP and ET-3, respectively (Komatsu et 
al., 1991; Ehrenreich et al., 1991). Although at present, little is 
known about the actions of CNP and ET-3 in the brain, i t is 
suspected that these two peptides may well interact within the 
CNS to regulate their central functions which may be related to 
their peripheral actions. Therefore, i t is worthwhile to study the 
interactions, if any, between these two peptides within the brain 
to obtain insight about their role(s) in the regulation of f lu id 
homeostasis and to explain the relationship between their central 
and peripheral effects. 
Although the central actions of CNP and ET-3 in the brain 
are largely unknown, recent studies on the cellular responses 
elicited by these two peptides have demonstrated that CNP is a 
potent stimulator of cGMP production in mouse astrocytes 
(Yeung et al” 1992a). Therefore, cGMP production was used as 
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the major parameter in this project to monitor the possible 
interaction between CNP and ET-3 in rat C6 glioma cells. This 
malignant cell line was employed in this study because they have a 
rather high proliferation rate. Thus, it should be advantageous to 
examine the relationship between these two peptides in the 
astrocytes to obtain some insights about the physiological 
difference between normal and malignant glial cells. 
The possible interaction between CNP and ET-3 on cGMP 
formation in rat C6 glioma cells was first examined to investigate 
the effect of ET-3 on CNP-dependent cGMP production. Then, 
several intracellular pathways were examined in order to identify 
the possible intracellular mechanisms involved in the action of 
ET-3. First, the PKC second messenger system was examined 
since ET-3 is known to activate PKC in other cell types (Simonson 
and Dunn, 1990; Masaki, 1991; Griending et al； 1989). Phorbol 12-
myristate 13-acetate (PMA), a potent PKC activator, was 
employed to test i f PKC activation can affect the CNP-induced 
cGMP formation. Also, three PKC inhibitors, staurosporine (ST), 
l-(5-isoquinoline sulfonyl)-2-methyl piperazine (H7) and 3-[l-[3-
(Amidinothio)propyl]-34ndolyl]-4-(l-methyl-3-indolyl)-lH-
pyrrole- 2,5- dione Methanesulfonate (Ro 31-8220), were tried to 
reverse the action of PMA to verify the effects induced by PMA. In 
addition, the PLA2 pathway was examined as ET-3 is shown to 
activate PLA2 in several cell types (Ritz et al" 1992; Simonson and 
Dunn, 1990; Masaki, 1991; Thomas et al" 1991; Resink et al" 1989). 
In addition to the study of interaction between CNP and ET-
3 on the cGMP system, some of the cellular metabolic processes 
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were also examined. First, since ET-3 can increase the 
intracellular calcium level in astrocytes (Goldman et al； 1991; 
Chuang et al； 1991), the effects of ET-3 and CNP on intracellular 
calcium uptake were studied to examine whether these two 
peptides interact through calcium transport in C6 cells. 
Second, as it is known that glial cells, especially astrocytes, 
play an important role in osmoregulatory functions and cellular 
volume control in the CNS (Pasantes-Morales et al, 1990), and 
that ANP and A VP, which regulate the systemic volume, are also 
involved in the volume regulation of brain cells (Doczi, 1993), the 
effects of CNP and ET-3 on cell volume changes were 
investigated. 
Third, in order to study the effects of CNP and ET-3 on 
different transport systems and to examine if these peptides act 
through Na+-dependent processes, the transport of glucose and 
several amino acids, such as taurine, glutamate, tyrosine and 
leucine, were examined. 
Finally, to further test the intracellular metabolic changes in 
C6 glioma cells induced by CNP and ET-3, cell proliferation, RNA 
synthesis and protein synthesis were examined using [^H]-
thymidine, [^HJ-uridine and [3H]~leucine, respectively. 
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Chapter 2 Methods 
2.1 In vitro culture of rat C6 glioma cells 
2.1.1 Preparation of reagents 
(1) Dulbecco's Modified Fagle Medium fDMFM^ 
DMEM wi th high glucose and L-glutamine was purchased 
from Gibco Lab. (Grand Island, NY, U.S.A.). Each pack (13.4g) of 
DMEM was made up to one liter with double distilled water and 
3.7g of sodium bicarbonate (NaHC〇3) was added to the medium 
solution. Then, the p H was adjusted to 7.2 using HC1. The 
solution was sterilized immediately by passing through a sterile 
mill ipore filter (0.2|nm, Micro Filtration Systems, Dublin, CA., 
U.S.A.) under suction and then stored at 4°C. 
(2) Phosphate buffered saline (PBS) 
PBS was prepared by dissolving 8.18g NaCl, 0.2g KC1, 0.2g 
K H 2 P O 4 and 1.44g Na2HP〇4.2H2〇 in one liter double distilled 
water. The p H was then adjusted to 7.4 with NaOH and sterilized 
by autoclaving at 121°C for 30 minutes. 
(3) Complete Dulbecco's Modified Eagle Medium 
(CDMEM) 
50ml Heat-inactivated horse serum (HIHS, horse serum 
heated at 56。C for 40 minutes, Gibco) and 10ml penicillin (10,000 
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I U / m l ) and streptomycin (10,000 [ig/ml) solution (Gibco) were 
added to 440ml sterilized DMEM to form CDMEM, which 
contained growth factors and nutrients necessary to support cell 
growth. Hence, CDMEM contains 10% (v/v) horse serum and 200 
I U / m l of penicillin and 200 | ig /ml of streptomycin. 
2.1.2 Culture of C6 glioma cells 
Rat C6 glioma cells were obtained from American Tissue 
Culture Association (Rockville, MD., U.S.A.). It is an adherent cell 
line and grows in a monolayer. They were cultured in CDMEM 
and were grown in 75cm2 tissue culture flask (Falcon, Becton 
Dickinson Labware, NJ, U.S.A.) at 37。C in a humidified incubator 
under an atmosphere of 5% C〇2/95% 〇2. 
Cells were subcultured twice a week under sterile condition. 
For subculturing, the old CDMEM was discarded and the cells 
were rinsed w i th 10ml of sterile PBS to remove most of the 
remaining serum which contained certain trypsin-inhibit ing 
factors that would inhibit the action of trypsin. Then, 0.5ml of 
0.25% trypsin (Gibco) was added to cover the monolayer 
completely. The flask was incubated at 37°C in an incubator for 3 
minutes fol lowed by shaking unti l all the cells were detached. 
Afterwards, 10ml of CDMEM was added to stop trypsinization. 
The cell suspension was transferred to a sterile centrifuge tube 
(Falcon, Becton Dickinson Labware, NJ, U.S.A.) and spun at 1000 
rpm for 4 minutes. The supernatant was discarded and the cell 
pellet was resuspended in 5ml of CDMEM. The cells were 
dispersed gently by pipetting. Cells were counted under a phase 
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contrast microscope and about 1.5 xl06 cells in 15ml CDMEM 
(prewarmed to 37°C) were subcultured in each 75cm2 flask. The 
flasks were capped and returned to the incubator. The cells used in 
this project were from 50 passages to 70 passages which had 
higher expression of GFAP. Fig. 2.1 showed the phase contrast 
micrograph of cultured rat C6 glioma cells, which were 
protoplasmic in shape wi th little branching process and resembled 
the shape of fibroblast. 
2.1.3 Cell plating in 6-well, 24-well and 96-well plastic trays 
The cells were harvested after trypsin digestion as described 
above. After centrifugation and resuspension in 5ml of CDMEM, 
cells were counted on a hematcytometer. lOjul of the cell 
suspension were mixed wi th 10|Lil of a trypan blue solution [ O.lg 
t rypan blue (Sigma Chemical Co., St Louis, MO, U.S.A.) 
dissolved in 50 m l PBS] and then applied to the hematcytometer. 
Since dead cells were stained blue wi th trypan blue and thus could 
be differentiated from the viable ones (Philip, 1973). The number 
of viable cells (V) was counted under light microscope. The viable 
cell concentration of the original cell suspension could then be 
calculated by the following equation: 
Total number of viable cells 
= V x 2 (dilution factor) x 5 (original cell volume) x 104 
For cell plating in 6-well and 24-well plastic trays, the cell 
suspension was diluted to about 4 x 105 cells/ m l wi th CDMEM, 
artd 1.5ml of the cell suspension was added to each well of a 6-
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Fig. 2.1: Phase contrast micrograph of cultured rat C6 glioma 
cells 
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well flat-bottomed plastic tray (Corning Glass Works, NY, U.S.A.) 
while 0.5ml of the cell suspension was added to each well of a 24-
wel l flat-bottomed plastic tray (Corning). On the other hand, for 
96-well plastic trays, the cell suspension was diluted to 2 x 105 
cells/ml in CDMEM, and 0.1ml of the cell suspension was added 
to each wel l of a 96-well flat-bottomed plastic tray (Corning). A l l 
the plates were cultured in a humidified incubator for 48 hrs to 
reach confluency. 
2.2 Determination of cGMP 
2.2.1 Measurement of cGMP 
cGMP level was determined by the cGMP [^H] assay kit 
purchased f r o m Amersham (U.K.). The assay, a 
radioimmunoassay (RIA), was based on the competition between 
unlabelled cGMP and a fixed quantity of the [3H]cGMP for 
binding to an antiserum which had a high specificity and affinity 
for cGMP. The amount of labelled cGMP bound to the antiserum 
was inversely related to the amount of cGMP present in the assay 
sample. In order to measure the antibody-bound labelled cGMP, 
antibody-bound cGMP was separated from the unbound one by 
ammonium sulphate precipitation followed by centrifugation. The 
precipitate containing the antibody-bound complex was then 
dissolved in water. The radioactivity was determined by l iquid 
scinti l lation counting using a Beckman scintillation counter 
(Model LS 1801). 
2.2.2 Data analysis 
40 
Methods 
The specific binding of [3H]-CGMP in a sample was obtained 
by substracting the counts per minute (cpm) determined in the 
absence of cGMP binding (blank) from the cpm determined in the 
presence of cGMP binding (sample). The specific binding in the 
absence of unlabelled cGMP (i.e. zero dose of unlabelled cGMP 
standard) was designated as C0 , while the specific binding in the 
presence of unlabelled cGMP from standard or unknown sample 
was designated as C x . The ratio of C 0 / C x was calculated from 
each sample (both standard and unknown). A linear calibration 
curve was obtained by plott ing C 0 / C x against picomoles of 
standard cGMP. The amount of cGMP in the unknown samples 
were then read off f rom the standard curve using their Co/Cx 
values (Fig. 2.2). 
2.3 Determination of the effect of CNP on cGMP production in 
C6 cells 
In order to study the effect of CNP on cGMP production, C6 
cells were pretreated w i t h human recombinant CNP-22 
purchased from Peninsula (U.S.A.). CNP was dissolved in double 
distilled water and diluted to 1 mM, aliquoted and stored at -70°C 
before use. 
In these experiments, monolayer cells cultured in 6-well 
plates were washed twice (2 x lml ) wi th SDMEM (supplemented 
DMEM) containing 5g /L bovine serum albumin (BSA; Sigma), 
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Fig. 2.2: A typical standard curve for cGMP determination. The 
specific b ind ing in the absence of unlabelled cGMP was 
designated as Co while the specific binding in the presence of 
unlabelled cGMP from standard was designated as Cx. Values 
were measured in duplicate according to the procedure in the 
Amersham cGMP assay kit. 
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(IBMX) (Sigma) as the phosphodiesterase inhibitor, and then 
equilibrated for 10 min at 37°C wi th l m l of SDMEM. 
To study the time course of cGMP formation, lOnM CNP 
was added to each wel l in the presence of IBMX ( ImM) and 
incubated for 1—60 min at 37。C. For the dose-response 
experiments, cells were incubated wi th different concentrations of 
CNP from 10-10—10"5 M for 10 min at 37°C . 
Intracellular cGMP level was measured using the method 
described by Yeung et al (1991b). In brief, the incubation was 
terminated by aspiration of the incubation medium and each well 
was rinsed wi th 2 x l m l of ice-cold PBS. Intracellular cGMP was 
released by adding l m l of 7.5% (w/v ) ice-cold trichloroacetic acid 
(TCA). After incubation at 4°C for 1 hr wi th occasional shaking, 
cells were scraped off, and the suspension was transferred to a 
microcentrifuge tube and centrifugated at 12,000 rpm for 5 min. 
The pellet was saved for protein determination (see below) while 
the supernatant was extracted six times w i th 4ml of water-
saturated diethyl ether to remove TCA. The residual trace of ether 
was removed by evaporation in a 40°C water bath. The aqueous 
layer was then lyophil ized and reconstituted in cGMP assay 
buffer (50mM Tris-HCl and 4mM EDTA, p H 7.5). Finally, cGMP 
in the sample was quantitated by RIA using the commercial cGMP 
RIA kit (Amersham, U.K.) as mentioned above. The ammonium 
sulfate precipitate containing the antibody-bound complex 
obtained in each tube was reconstituted in 200|il doubled distilled 
water, and l m l scintillant (0.4g POPOP, 4g PPO dissolved in 1L 
mixture of 666ml toluene and 333ml triton-XlOO) was added to 
4 3 
~ “ Methods 
each tube. After mixing, the radioactivity was quantitated by 
l iquid scintillation counting (Beckman Model LS 1801). 
The TCA precipitate obtained after centrifugation was 
solubilized w i th l m l of 1% sodium dodecyl sulfate (SDS). 50|il of 
solubil ized solution f rom each tube was used for protein 
determination using the Folin method (Lowry et al” 1951) wi th 
BSA (Sigma) as the standard. Protein concentration was 
determined by reading the absorbance at 750nm using a Shimadzu 
UV-1201 spectrophotometer. 
The results were expressed as pmol cGMP/mg of protein 
and each experiment was performed in triplicate and repeated 
three times. 
2.4 Determination of the effect of ET-3 on the action of CNP in 
C6 cells 
2,4.1 Measurement of intracellular cGMP levels affected by 
ET-3 
In order to study the effect of ET-3 on cGMP production, C6 
cells were pretreated w i th human recombinant ET-3 purchased 
from Peninsula (U.S.A.). ET-3 was dissolved in double distilled 
water and diluted to ImM, aliquoted and stored at -70°C before 
use. 
In this experiment, monolayer cells cultured in 6-well plates 
were washed twice wi th SDMEM at 37。C and then equilibrated 
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for 10 min wi th l m l of SDMEM. After equilibration, lOOnM ET-3 
in l m l SDMEM containing I m M of IBMX was added to each 
wel l and incubated for 20 min at 37。C. The incubation was 
terminated by aspiration of the incubation medium and each well 
were rinsed wi th 2 x l m l of ice-cold PBS. Intracellular cGMP was 
released by adding l m l of 7.5% (w /v ) ice-cold TCA, and the 
amount of cGMP and protein in the samples were quantitated in 
the same manner as that for the CNP-treated samples (see 
Section 2.3). The results were expressed as pmol cGMP/mg of 
protein. This experiment was performed in triplicate and 
repeated two times. 
2.4.2 Measurement of intracellular cGMP levels affected by 
CNP w i th ET-3 pretreatment 
In order to study the interaction between ET-3 and CNP on 
cGMP production, C6 cells cultured in 6-well plates were 
pretreated wi th ET-3 before they were incubated wi th CNP. 
As described before, cells were washed twice wi th SDMEM 
at 37°C and then equilibrated for 10 min wi th l m l of SDMEM. To 
study the effect of ET-3 exposure time on the action of CNP on 
cGMP formation, C6 cells were pretreated w i th lOOnM ET-3 in 
l m l SDMEM containing I m M of IBMX at 37。C for various 
intervals between 1一60 min. For the ET-3 dose-response 
experiments, cells were incubated wi th different concentrations of 
ET-3 from 10_5M for 20 min at 37°C. Then, lOnM CNP was 
added and the cells were further incubated for 10 min. 
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The incubation was terminated by aspiration and the cells 
were rinsed w i th 2 x l m l of ice-cold PBS. Intracellular cGMP 
formed and the amount of protein in each sample were 
determined in the same manner as described above (see Section 
2.3). The results were expressed as pmol cGMP/mg of protein and 
each experiment was performed in triplicates and repeated three 
times. 
2.5 Determination of the effects of PKC activator and inhibitor 
on CNP-treated C6 cells 
2.5.1 Measurement of intracellular cGMP levels affected by 
PKC activator or inhibitor 
In order to study if activation or inhibition of PKC would 
affect cGMP production, C6 cells were pretreated wi th a potent 
PKC activator, phorbol 12-myristate 13-acetate (PMA, Sigma); 
three PKC inhib i tors, staurosporine (ST, Sigma), 1 -(5-
isoquinoline sulfonyl)-2-methyl piperazine (H7, Sigma) and 3-[l-
[3-(Amidinothio) propyl]-3-indolyl]-4-(l-methyl-3-indolyl)-lH-
pyrrole- 2,5- dione Methanesulfonate (Ro 31-8220, Roche 
Products Ltd, U.K.). These four PKC agents were dissolved in 
dimethylsulfoxide (DMSO; Sigma) and diluted to ImM, aliquoted 
and stored at -20°C before use, except for Ro 31-8220 which was 
stored at -70°C. 
In these experiments, monolayer cells cultured in 6-well 
plates were washed and equilibrated wi th SDMEM as described 
in Section 2.3. After equilibration, PMA ( lOOnM), ST ( lOOnM ), 
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H7 (l^lM) or Ro 31-8220 ( lOOnM) in l m l SDMEM containing 
I m M IBMX was added to each well. In experiments wi th PMA, 
cells were incubated for 20 min while in other experiments cells 
were incubated for 30 min at 37。C. The incubation was terminated 
by aspiration and the cells were rinsed wi th 2 x l m l of ice-cold 
PBS. Intracellular cGMP formed and the amount of protein in 
each well were determined as described in Section 2.3. The results 
were expressed as pmol cGMP/mg of protein and each 
experiment was performed in triplicate and repeated two times. 
2.5.2 Measurement of intracellular cGMP levels affected by 
CNP with PKC activator or inhibitor pretreatment 
In order to study if activation or inhibition of PKC would 
affect the action of CNP on cGMP production, C6 cells were 
pretreated w i th PMA or each of the three PKC inhibitors, ST, H7 
and Ro 31-8220, before CNP incubation! 
In these experiments, monolayer cells cultured in 6-well 
plates were washed and equilibrated wi th SDMEM - (see Section 
2.3). In order to study the effect of PKC activator on the action of 
CNP on cGMP production, both the effect of PMA exposure time 
and its dose-dependent effect was studied. To study the time 
course of the effect of PMA, cells were pretreated wi th lOOnM 
PMA in l m l SDMEM containing I m M of IBMX for various 
intervals between 1—60 min at 37°C, while for the dose-response 
experiments, cells were incubated wi th different concentrations, 
from 10-10—10-5M, of PMA for 20 min at 37°C. Then, lOnM CNP 
was added and further incubated for 10 min. To study the effects 
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of PKC inhibitors, ST (lOOnM), H7 ( 1|LIM) or Ro 31-8220 (lOOnM) 
in l m l SDMEM containing I m M of IBMX was added to each 
wel l and the cells were incubated for 30 min at 37。C before lOnM 
CNP was added and further incubated for 10 min. 
The incubation was terminated by aspiration and the cells 
were rinsed w i th 2 x l m l of ice-cold PBS. Intracellular cGMP 
formed and the amount of protein in each well were determined 
as described before (see Section 2.3). The results were expressed 
as pmol c G M P / m g of protein and each experiment was 
performed in triplicates and repeated three times. 
2.5.3 Measurement of intracellular cGMP levels affected by 
CNP wi th PKC inhibitor antagonized PMA or ET-3 
pretreatment 
In order to study if PKC inhibitors were able to antagonise 
the effects of PMA or ET-3 on the CNP-affected cGMP 
production, C6 cells were pretreated wi th PKC inhibitors before 
the addition of PMA or ET-3, and then subsequently incubated 
w i th CNP. 
In these experiments, monolayer cells cultured in 6-well 
plates were washed and equilibrated wi th SDMEM (see Section 
2.3). After equilibration, l m l SDMEM containing I m M of IBMX 
and one of the following PKC inhibitors, ST (lOOnM), H7 (l^iM) or 
Ro 31-8220 (lOOnM), was added to each well and incubated for 30 
min at 37°C. Then, cells were incubated wi th PMA (lOOnM) or 
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ET-3 (lOOnM) for 20 min at 37。C. Afterwards, lOnM CNP was 
added and the cells were further incubated for 10 min. 
The incubation was then terminated by aspiration and the 
cells were rinsed wi th 2 x l m l of ice-cold PBS. Intracellular cGMP 
formed and the amount of protein in each well were determined 
in the same manner as described above (see Section 2.3). The 
results were expressed as pmol cGMP/mg of protein and each 
experiment was performed in triplicate and repeated three times. 
2.6 Determination of the effect of arachidonic acid on the action 
of CNP in C6 cells 
To examine if arachidonic acid would affect the action of 
CNP on cGMP production, C6 cells were pretreated w i th 
arachidonic acid (Sigma) before they were incubated wi th CNP. 
In this experiment, monolayer cells cultured in 6-well plates 
were washed and equilibrated in the same manner as described 
before (see Section 2.3). After equilibration, arachidonic acid 
( l j iM) in l m l SDMEM containing I m M of IBMX was added to 
each wel l and incubated for 30 min at 37。C. Then, lOnM CNP was 
added and the cells were further incubated for 10 min. 
The incubation was terminated by aspiration and the cells 
were rinsed w i th 2 x l m l of ice-cold PBS. Intracellular cGMP 
formed and the amount of protein in each well were determined 
in the same manner as described above (see Section 2.3). The 
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results were expressed as pmol cGMP/mg of protein and the 
experiment was performed in triplicate and repeated three times. 
2.7 Determination of the effects of ET-3 and CNP on calcium 
uptake in C6 cells 
Prior to the experiment, C6 cells cultured in 24-well plates 
were washed twice (2 x 0.5ml) w i th low calcium (0.03mM Ca^+) 
MCDB 151 med ium (Sigma) prewarmed to 37°C, and then 
equilibrated for 10 min w i th 0.5ml of MCDB 151 medium. After 
equi l ibrat ion, cells were preincubated w i t h ET-3 (lOnM or 
lOOnM), CNP (lOnM or lOOnM), or different combinations or 
these two peptides, in 0.25ml MCDB 151 medium for 20 min at 
37°C. The cells were then incubated w i th 5 | iC i /m l of 4 5 Ca 2 + 
(specific activity: 780.67Ci/mmol, Amersham, U.K.) in 0.25ml 
MCDB 151 medium for 5 min at 37°C. Subsequently, the medium 
i n each we l l was discarded and the cells were washed 
immediately w i th 2 x l m l ice-cold physiological buffer containing 
140mM NaCl , 3 m M KC1, 1.2mM M g C l 2 . 6 H 2 〇，3 m M 
CaCl2 .2H2〇，5mM HEPES and lOmM glucose, and then 
solubilized overnight w i th 0.2ml 1M NaOH w i th shaking. The 
radioactivities in 100|il aliquot of the solubilized cells and 100|nl of 
incubation med ium were quantitated by l iqu id scintillation 
spectrometry, and 80|Lil aliquot of solubilized cells were used for 
protein determination using Folin method w i th BSA as the 
standard. The results were expressed as pmole of calcium uptake 
per mg of cellular protein in each culture wel l (pmol /mg of 
protein) and the equation used for calculation of 45Ca^+ uptake is: 
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Fraction of 45ca2+uptake, (A)= 
2 x Radioactivity of 100叫 solubilized solution (cpm) 
2.5 x Radioactivity of 45ca2+ in the incubation medium (cpm) 
Calcium uptake = (A x B ) /C 
where, A = fraction of 45Ca2+ uptake 
B = 7500 pmole (amount of Ca2 + in each well) 
C = amount of protein in each well (mg) 
Calcium uptake in different groups were compared using 
Student's t -test, wi th significance of p<0.05, and the experiments 
were repeated three times in quadruplicates. 
2.8 Determination of the effects of CNP and ET-3 on cell 
volume change in C6 cells 
3-0-methyl-D-[l-3H]-glucose (30MG, Amersham, U.K.) is 
a non-metabolizable glucose analog used in this project to study 
the effects of CNP and ET-3 on cell volume changes. This analog 
had been employed as index of cell volume because it is taken up 
into the cells w i th water unt i l equil ibrium (Kimelberg and 
Frangakis, 1985). 
In these experiments, cells cultured in 24»well plates were 
washed twice (2 x 0.5ml) wi th SDMEM and equilibrated wi th 
0.5ml SDMEM for 10 min at 37°C. Subsequently, the cells were 
incubated wi th CNP (lOOnM ), ET-3 (200nM), both CNP and ET-3, 
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PMA (lOOnM), or dbcGMP (10|LIM) in 0.25ml S D M E M for 24 hrs 
in an humidi f ied incubator at 37。C prior to the 3 0 M G uptake 
assay. Before the assay, cells were washed twice (2 x 0.5ml) w i th 
physiological buffer (without glucose) prewarmed to 37。C, and 
then incubated w i t h I p C I / wel l of 3 0 M G (specific activity: 
3.4Ci/mmol) in 0.25ml of physiological buffer for 10 min at 37°C. 
A t the end of the incubation, the medium was removed and the 
cells washed w i th 2 x l m l ice-cold physiological buffer containing 
glucose. Cells were solubil ized w i t h 0.2ml 1M NaOH. The 
amounts of radioactivity and protein were determined in the 
same manner as that for calcium uptake. The results were 
expressed as |Lil of water /mg of protein and the equations used for 
calculation of intracellular water is: 
Fraction of [3H]-30MG uptake = 
Total radioactivity in solubilized cells (cpm) 
Total radioactivity of [3H]-30MG in the incubation medium (cpm) 
Intracellular water ( | i l )= 
Fraction of [3H]-30MG uptake x 250 (\il) 
mg of protein in each wel l 
Intracellular water in different groups were compared using 
Student's t -test, w i th significance of p<0.05, and the experiments 
were repeated three times in quadruplicates. 
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2.9 Determination of the effects of CNP and ET-3 on glucose 
and amino acids uptake in C6 cells 
2.9.1 Measurement of glucose uptake in CNP- and/ or ET-
3- treated C6 cells 
3〇MG was used to determine the effects of CNP and ET-3 
on glucose uptake. In these experiments, cells cultured in 24-well 
plates were washed, equilibrated and incubated wi th CNP, ET-3, 
PMA and dbcGMP in the same manner as described in Section 2.8. 
The cells were then washed twice (2 x 0.5ml) wi th physiological 
buffer (without glucose) prewarmed to 37。C prior to the assay, 
and then incubated wi th 0.5(iCi/ well of 30MG (specific activity: 
3.4Ci/mmol) at a final concentration of 0.3mM of glucose in 
0.25ml of physiological buffer for 40 min at 37°C. At the end of the 
incubation, the medium was removed and the cells washed with 2 
x l m l ice-cold physiological buffer containing glucose. Cells were 
solubilized w i th 0.2ml 1M of NaOH. The amount of radioactive 
glucose analog and the amount of protein were determined in the 
same manner as that for calcium uptake. The Results were 
expressed as nmole of glucose uptake per mg of cellular protein in 
each culture well (nmol/mg of protein) and the equation used to 
calculate glucose uptake is similar to that for calcium uptake. 
Glucose uptake in different groups were compared using 
Student's t -test, wi th significance of pcO.05, and the experiments 
were repeated three times in quadruplicates. 
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2.9.2 Measurement of amino acid uptake in CNP- and/or 
ET-3 treated C6 cells 
The procedure and treatments were similar to those 
described for glucose uptake (see Section 2.9.1). Briefly, cells 
cultured in 24-well plates and primed wi th CNP, ET-3, PMA or 
dbcGMP were incubated w i th 0.25ml of physiological buffer 
containing 0.2| iCi /wel l of [ l ,2-3H]taurine (specific activity: 
28Ci/mmol), L-[3,5-3H]tyrosine (specific activity: 45Ci/mmol), L-
[G-3H]glutamic acid (specific activity: 46Ci/mmol) or L-[4,5-
3H]leucine (specific activity: 164Ci/mmol) (all from Amersham, 
U.K.), each at a final concentration of 0.3mM, for 40 min at 37。C. 
At the end of the incubation, the medium was aspirated and 
the cells washed wi th 2 x l m l ice-cold physiological buffer. Then, 
0.2ml 7.5% ice-cold TCA was added to each well and the culture 
plates were kept at 4°C overnight to precipitate cellular proteins. 
The radioactivity in 100|il of TCA soluble fraction was counted; 
while the TCA-insoluble fraction was solubilized wi th 0.2ml 1M of 
NaOH, and 100|Lil of the solubilized TCA-precipitate was taken 
for radioactivity measurement to determine the amount of 
radioactivity incorporated into protein. Another 80(il of the 
solubi l ized TCA-precipi tate was removed for protein 
determination. Results and data were treated as described for 
glucose uptake (see Section 2.9.1). The results were expressed as 
nmole of amino acid uptake per mg of cellular protein in each 
culture wel l (nmol /mg of protein), and the experiments were 
repeated three times in quadruplicates. 
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2.10 Determination of thymidine, uridine and leucine 
incorporation in CNP- and/or ET-3-treated C6 cells 
C6 cells were cultured in 96-well plates and was primed 
w i th CNP (lOOnM), ET-3 (200nM), both CNP and ET-3, PMA 
(lOOnM), dbcGMP (IO^IM) or dbcAMP (10|LIM) in 0.1ml SDMEM 
for 24 hrs at 37。C prior to incorporation studies. 0.5|iCi/well of 
labelled substrates, [methyl-3H]thymidine (specific activity: 
2Ci/mmol), [5-3H]uridine (specific activity: 27Ci/mmol) or L-[4,5-
3H]leucine (specific activity: 164Ci/mmol) ( lmCi /ml , Amersham, 
U.K.) was added to each wel l in 100|il SDMEM and further 
incubated for 6 hrs at 37°C. At the end of the incubation, the 
medium was aspirated and the cells washed twice wi th ice-cold 
physiological buffer. Afterwards, 0.2ml 7.5% ice-cold TCA was 
added and the cells were kept at 4°C overnight to precipitate all 
proteins, and the cells were harvested using microplates cell 
harvestor (semi-automatic Titertek Cell Harvester) which 
transferred the labelled proteins to the glassfiber filter paper 
(GF/C; Maidstone, England). The filter paper was then dried and 
the labelled substrate incorporated was determined by l iquid 
scintillation counting. The results were expressed as cpm/wel l 
and each experiment was repeated three times w i th each 
treatment performed six times. 
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Chapter 3 Results 
3.1 Effects of CNP and ET-3 on cGMP production in cultured 
rat C6 glioma cells 
Since CNP was able to increase cGMP synthesis in mouse 
astrocytes (Yeung et al； 1992a) and ET-3 was secreted by and 
bound specifically to rat astrocytes (Ehrenreich et al., 1991), the 
effects of CNP and ET-3 on cGMP production in C6 glioma cells 
were examined in the present study. In order to study their effects 
on cGMP production, first, the effects of various concentrations 
of CNP and the time course of cGMP accumulation in C6 cells 
were studied to obtain the optimal dose and incubation time of 
CNP on cGMP formation. Second, cGMP formation in cells 
pr imed w i th various concentration of ET-3 and for different 
periods of time before exposed to CNP were studied. This is to 
investigate if CNP and ET-3 have antagonistic effects on cGMP 
production in C6 cells. This is important as it has been shown that 
these two peptides have oppositer biological actions in various 
tissues (Marin-Grez et al" 1986; Yanagisawa et al, 19S8; Badr et 
al； 1989; Kohno et al., 1993). Third, since ET-3 is a PKC activator 
(Griendling et al, 1989), in order to investigate if this peptide 
exerts its action on CNP-affected cGMP production via PKC 
activation, the effect of PMA, a potent PKC activator, on CNP-
affected cGMP production, and the possible antagonism by 
several PKC inhibitors were studied. Fourth, since it was 
observed that ET could activate PLA2 in some other cell types, eg. 
rat nerve cells, smooth muscle cells and mesangial cells (Ritz et 
a l ) 1992; Resink et al., 1989; ), the effect of arachidonic acid on 
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CNP-stimulated cGMP formation was studied to investigate if 
the PLA2 activation is involved in the inhibitory action of ET-3 on 
CNP-stimulated cGMP accumulation. 
3.1.1 Effect of CNP on cGMP production in cultured C6 
glioma cells 
The effects of CNP on cGMP synthesis in C6 glioma cells 
were studied by incubating the cells w i th CNP for different 
periods of time and in the presence of various concentrations of 
this peptide. The results of these studies can provide the optimal 
incubation conditions for CNP-induced cGMP formation, and 
also information on the concentration dependence of CNP on 
cGMP levels in C6 glioma cells. 
3.1.1.1 The time course of CNP on cGMP 
production 
Preliminary studies showed that CNP at lOnM stimulated 
cGMP product ion in cultured C6 glioma cells, and this 
concentration was used initially to study the time course of the 
effect of CNP on cGMP formation. 
Fig. 3.1 showed the results of cGMP production in C6 cells 
primed w i th lOnM of CNP. Significant time-dependent increase 
in cGMP production in the presence of lOnM of CNP was 
observed from 0.5 min to 60 min, and maximum cGMP production 
was reached at 30 min. The cGMP level increased from a baseline 
value of 0.8 士 0.2 pmol /mg of protein to a maximal value of 13.3 土 
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Fig. 3.1: Time course of the effect of CNP on cGMP production 
i n C6 glioma cells. Confluent cells were equilibrated wi th 
SDMEM for 10 min and then incubated wi th lOnM CNP at 37。C 
for different durations as shown. Intracellular cGMP was 
determined as described in the Methods (Section 2.3). Values 
shown are means 士 SD of three experiments each in triplicates. * 
p<0.05, significantly different from the corresponding control by 
using Student's t -test. 
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3.0 p m o l / m g of protein at 30 min of CNP incubation. As no 
significant difference was observed among CNP-induced cGMP 
production at 10, 30 and 60 min, which were 8.0 士 1.1 pmol /mg of 
protein, 13.3 土 3.0 pmo l /mg of protein and 9.0 士 1.2 pmol /mg of 
protein, respectively, subsequent incubations w i th CNP were 
carried out for 10 min. 
3.1.1.2 Dosage-response of CNP on cGMP 
production 
As described above, lOnM of CNP was found to have a 
stimulatory effect on cGMP production. In this study, several 
concentrations, between 10-10—10-5m of CNP, were used to test 
whether its effect was dose-dependent. In these experiments, C6 
cells were incubated wi th different concentrations of CNP for 10 
min. 
Fig. 3.2 showed the cGMP production in C6 glioma cells. No 
significant stimulation of cGMP production was observed wi th 
10-n to 10-9M of CNP, while CNP above lO—M induced cGMP 
product ion in a dose-dependent manner. The cGMP level 
increased from a baseline value of 0.5 士 0.1 pmol /mg of protein to 
a maximal value of 16.4 士 1,1 pmol /mg of protein in the presence 
of 10|nM of CNP. The half-maximal effective concentration 
( E C 5 0 ) of CNP was determined to be 17nM. Since lOnM CNP was 
able to increase the cGMP level from 0.5 士 0.1 pmol /mg of protein 






18 - * 
16 - ^ 
L 14" # Vi 
M 12: 
i i 1 0 ； • 乂 
1 1 : : 广 
/ * p<0.05 
2 : _ _ / 
0 I f I I III| I I I I III I| 1 I I I 11 m I I I I 11 m I I I 111 II| I I I I I III| 
0 10 " 1 0 10 " 9 1 0 - 8 10 " 7 10 ' 6 10 " 5 10 ' 4 
CNP (M) 
Fig. 3.2: Dose-dependent effect of CNP on cGMP production 
in C6 cells. Confluent cells were equilibrated wi th SDMEM for 10 
min and incubated wi th various concentrations of CNP for 10 min 
at 37°C. cGMP was quantified as described in the Methods 
(Section 2.3). Values shown are means 士 SD of three experiments 
each in triplicate. * p<0.05, significantly different from the control 
([CNP] = 0) by using Student's t -test. 
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3.1.2 Effect of ET-3 on cGMP production in C6 glioma cells 
Since NP and ET have opposite biological actions in various 
tissues (Marin-Grez et al., 1986; Yanagisawa et al； 1988; Badr et 
a l . ' 1989; Kohno et al., 1993), it is worthy to study the possible 
effect of ET-3 on CNP-induced cGMP production in C6 cells. In 
this study, the effects of various exposure time to and different 
doses of ET-3 on CNP-induced cGMP responses were examined. 
3.1.2.1 Effect of ET-3 on basal cGMP production 
Before studying the time course and dose-dependent effect 
of ET-3 on CNP-induced cGMP production, it is important to 
make sure if ET-3 itself w i l l have any effect on cGMP levels in C6 
glioma cells. In this study, lOOnM of ET-3, a relatively high 
concentration which had been shown to have secretory and 
mitogenic effects on other cell types (Samson et al., 1991b; 
MacCumber et ah, 1990), was used to test its effect on cGMP 
formation in C6 cells. 
Fig. 3.3 showed the effect of ET-3 on cGMP production. 
After 20 min of incubation, lOOnM of ET-3 slightly increased the 
cGMP from a baseline of 0.8 士 0.1 pmol /mg of protein to 1.0 士 0.2 
pmo l /mg of protein. This finding suggests that ET-3 did not affect 
the formation of cGMP significantly in C6 cells. 
3.1.2.2 Effect of pre-exposure duration to ET-3 on 
CNP-induced cGMP formation 
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Fig. 3.3: The effect of ET-3 on cGMP production in C6 cells. 
Confluent cells were equilibrated wi th SDMEM for 10 min and 
incubated wi th lOOnM ET-3 for 20 min at 37。C. cGMP level was 
measured as described before (Section 2.3). Values shown are 
means 士 SD of two experiments each in triplicate. 
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Preliminary studies showed that ET-3 at lOOnM could 
attenuate the CNP-induced cGMP formation in cultured C6 
glioma cells and this concentration was used initially to study the 
effect of ET-3 on CNP-induced cGMP formation. In these 
experiments, cells were incubated wi th lOOnM of ET-3 for various 
time periods and followed by incubation wi th lOnM of CNP for 
another 10 min to examine the effect of pre-exposure duration to 
ET-3 on the inhibitory action of ET-3 on CNP-induced cGMP 
accumulation. 
Fig. 3.4 showed the effects of several preincubation periods 
w i t h lOOnM of ET-3 on CNP-induced cGMP formation. 
Preincubation of C6 cells wi th lOOnM of ET-3 for time intervals, 
varying between 1—20 min, showed progressive suppression of 
CNP-induced cGMP formation and no further inhibit ion was 
observed after 20 min. After 20 min of pre-exposure to lOOnM of 
ET-3, cGMP level was reduced from 23.8 ±2.1 pmol /mg of protein 
in the presence of lOnM CNP alone to 7.5 土 1.8 pmo l /mg of 
protein. The effect of ET-3 on CNP-induced cGMP production 
appeared to be rather rapid as 1 min preincubation wi th ET-3 
already caused a profound (70%) inhibition on CNP-dependent 
cGMP formation. Since there was no significant difference in 
CNP-induced cGMP formation between cells pre-exposed to ET-
3 for 20 min and 60 min, 20 min preincubation wi th ET-3 was used 
for subsequent experiments. 
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Fig. 3.4: Effects of preincubation time w i th ET-3 on CNP-
induced cGMP production in C6 glioma cells. Cells were 
equilibrated w i th SDMEM for 10 min and preincubated wi th 
lOOnM ET-3 at 37。C for different durations as shown, then 
exposed to lOnM CNP in SDMEM or SDMEM alone for 10 min. 
Cells incubated without either peptide for the same periods of 
time served as the respective controls. cGMP level was measured 
as described before (Section 2.3). Values shown are means 土 SD of 
three experiments each in triplicate. *p<0.05' significantly 
different from the corresponding time periods treated wi th CNP 
alone by using Student's t -test. 
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In preliminary experiments, lOOnM of ET-3 was found to 
have inhibitory actions on CNP-induced cGMP formation. In this 
study, varying concentrations of ET-3, from 10_10 to 2 x 10_6M, 
were used to test whether the inhibitory effect of this peptide on 
CNP-induced cGMP formation was dose-dependent. Briefly, C6 
cells were treated w i t h varying concentrations of ET-3 as 
indicated in Fig. 3.5 for 20 miri. Incubation was continued for 
another 10 min in the presence of lOnM of CNP and intracellular 
cGMP levels determined. 
Fig. 3.5 showed the amounts of cGMP accumulation in C6 
cells obtained in this study. Exposure to lOnM of CNP stimulated 
cGMP production from a basal value of 1.0 土 0.2 pmol /mg of 
protein to 16.8 ±1.2 pmo l /mg of protein. ET-3 suppressed CNP-
stimulated cGMP production in a dose-dependent fashion, with a 
half-maximal inhibi tory concentration ( I C 5 0 ) of 1.4nM, and 
maximum inhibi t ion was observed w i th 2| iM of ET-3, which 
resulted in a 76% reduction of CNP-induced cGMP formation. 
Since lOOnM of ET-3 was able to inhibit the CNP-induced cGMP 
production f rom 16.8 土 1.2 pmo l /mg of protein to 6.0 士 0.3 
p m o l / m g of protein, lOOnM of ET-3 was selected for the 
subsequent studies. 
3.1.3 Effect of PMA on cGMP production in C6 glioma cells 
In previous experiments, ET-3 was shown to have potent 
inhibition on CNP-induced cGMP formation in C6 cells; however, 
the underlying mechanism remains unclear. Since ET-3 has been 
shown to activate PKC w i th high potency (Griendling et al, 
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Fig. 3.5: Dose-dependent effect of ET-3 on CNP-induced 
cGMP production in C6 glioma cells. Cells were equilibrated wi th 
SDMEM for lOmin and preincubated wi th various concentrations 
of ET-3, as shown, for 20 min at 37。C, then exposed to lOnM CNP 
in SDMEM or SDMEM alone for 10 min. cGMP level was 
measured as described before (Section 2.3). Control experiments 
were carried out under the same condit ion w i th respective 
concentrations of ET-3 but without the addition of CNP. Values 
shown are means 土 SD of three experiments each in triplicate. * 
p<0.05, significantly different f rom the treatment without ET-3 
preincubation by using Student's t -test. 
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1989), therefore, the effect of PMA, an activator of PKC, was 
tested to see if the effect of ET-3 was mediated through PKC 
activation. 
3.1.3.1 Effect of PMA on basal cGMP production 
Before studying the effect of PMA on CNP-stimulated 
cGMP formation, it is necessary to test if PMA itself would affect 
the cGMP production in C6 cells. In this study, C6 cells were 
incubated w i th lOOnM of PMA for 20 min to test its effect on 
cGMP production in C6 glioma cells. This concentration of PMA 
was chosen as lOOnM of PMA had been shown to activate PKC in 
smooth muscle cells (Stassen et al； 1989). 
The addition of lOOnM of PMA only caused a slight increase 
in cGMP level from 0.8 土 0.1 pmo l /mg of protein to 1.1 土 0.1 
p m o l / m g of protein (Fig. 3.6). Therefore, i t appeared that 
incubation of C6 cells wi th lOOnM of PMA, which had been shown 
to activate PKC in smooth muscle significantly (Stassen et al" 
1989), d id not affect cGMP formation. Since longer incubation 
period d id not affect cGMP formation and that PMA is a fairly 
lipid-soluble compound, it seems reasonable to conclude that PMA 
has no effect on the basal levels of cGMP. 
3.1.3.2 Effect of pre-exposure duration to PMA on 
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Fig. 3.6: The effect of PMA on cGMP production in C6 cells. 
Cells were equilibrated wi th SDMEM for 10 min and incubated 
w i th lOOnM PMA for 20 min at 37。C. cGMP level was measured 
as described before ( Section 2.3). Values shown are means 土 SD 
of two experiments each in triplicate. * p<0.05, significantly 
different from the control by using Student's t -test. 
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In order to study the effect of pre-exposure duration to PMA 
on CNP-induced cGMP formation, C6 cells were preincubated 
w i th lOOnM of PMA for various time periods before incubated 
wi th lOnM of CNP for another 10 min. 
Preincubation of cells w i th lOOnM of PMA for time 
intervals, varying between 1一60 min (as shown in Fig. 3.7), 
produced a progressive suppression of CNP-induced cGMP 
accumulation, and maximum inhibition was observed at 10 min of 
pre-exposure (Fig. 3.7). After 10 min exposure to lOOnM of PMA, 
the CNP-induced cGMP production decreased from a maximum 
of 20.4 土 1.8 pmol /mg of protein to 10.7 士 1.3 pmol /mg of protein. 
More prolonged exposure to PMA, up to 60 min, did not further 
suppress CNP-induced cGMP formation significantly. Since there 
was no significant difference in the inhibitory action of the PMA 
preincubation after 10 min, a 20 min preincubation time was used 
for subsequent experiments. 
Like the action of ET-3, PMA (lOOnM) induced a profound 
(60%) inhibit ion in CNP-stimulated cGMP formation after 2 min 
exposure to this PKC activator. However, the effect of PMA 
appeared to be less rapid and pofound, as ET-3 could cause 70% 




“p<0.05, compared with CNP (-PMA) 
4 Control 
25 -
— O C N P (-PMA) 
I ~ • C N P (+PMA) 
I t . 
S^ s 15 - O I 
w bo 
|| 仏 ^ . 
I I io- H i I * 
5 - 丄 
I 5 
o H 1 1 1 1 " 1 « 1 “ 1 “ 1 » 1 • 
-10 0 10 20 30 40 50 60 70 
PMA preincubation (min) 
Fig. 3.7: Effects of preincubation time w i th PMA on CNP-
induced cGMP production. Cells were equilibrated wi th SDMEM 
for 10 m in and preincubated w i th lOOnM PMA at 37。C for 
different durations as shown, then exposed to lOnM CNP for 10 
min. Cells incubated without either peptide for the same periods 
of time served as the respective controls. cGMP level was 
measured as described before (Section 2.3). Values shown are 
means 土 SD of three experiments each in triplicate. ^<0.05, 
significantly different f rom the corresponding time periods 
treated w i th CNP alone by using Student's t -test. 
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3.1.3.3 Dosage-response of PMA on CNP-induced 
cGMP production 
In this study, varying concentrations of PMA, from lO-iO to 
10_5m, were used to investigate if the inhibitory effect of this PKC 
activator was dose-dependent. 
Brief ly, C6 gl ioma cells were treated w i th varying 
concentrations of PMA as shown, in Fig. 3.8 for 20 min at 37°C. 
Incubation was continued for another 10 min in the presence of 
CNP (lOnM) and intracellular cGMP levels determined. lOnM of 
CNP stimulated cGMP production from a basal value of 1.2 士 0.2 
pmo l /mg of protein to 20.7 土 3.8 pmol /mg of protein (Fig. 3.8). 
PMA suppressed CNP-stimulated cGMP production in a dose-
dependent fashion, w i th an IC50 of 2nM; maximum inhibition 
was observed wi th 10|LiM of PMA, and this concentration of PMA 
resulted in a 70% reduction of cGMP formation stimulated by 
lOnM of CNP. 
From this and the previous studies wi th ET-3, i t appeared 
that ET-3 was a l itt le more rapid and potent than PMA in 
suppressing CNP-augmented cGMP formation. This was 
supported by several findings, first, the IC50 value of ET-3, which 
was determined to be 1.5nM, was slightly lower than 2nM 
determined for PMA; second, ET-3 produced a slightly greater 
inhibition of up to 76% in CNP-dependent cGMP formation while 
PMA induced a maximum inhibition of 70% in cGMP response; 
and third, the effect of ET-3 was more rapid (after 1 min 
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Fig. 3.8: Dose-dependent effect of PMA on CNP-induced 
cGMP production in C6 cells. Cells were equilibrated wi th 
SDMEM for lOmin and preincubated wi th various concentrations 
of PMA, as shown, for 20 min at 37°C, then exposed to lOnM CNP 
in SDMEM or SDMEM alone for 10 min. cGMP level was 
measured as described before (Section 2.3). Control experiments 
were carried out under the same condition w i th respective 
concentrations of PMA but without the addition of CNP. Values 
shown are means 土 SD of three experiments each in triplicate. * 
p<0.05, significantly different from the treatment without PMA 
preincubation by using Student's t -test. 
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preincubation). In view of the fact that PMA is a potent PKC 
activator in other tissues (Stassen et al, 1989), the effect of ET-3 
on CNP-dependent cGMP formation may not be solely mediated 
through PKC activation. If the effect of ET-3 was mainly 
mediated via PKC activation, one would expect that PMA, a 
potent PKC activator, should be much more potent and rapid. 
3.1.4 Effects of PKC inhibitors on cGMP production in C6 
glioma cells 
In order to confirm that the inhibitory effect of PMA on 
CNP-stimulated cGMP formation was due to the specific 
activation of PKC by ET-3, the effects of several PKC inhibitors 
were tested to see if these inhibitors can reverse the inhibitory 
action of ET-3 and PMA. 
3.1.4.1 Effects of PKC inhibitors on basal cGMP 
production 
In this study, C6 glioma cells were incubated wi th lOOnM of 
ST, l | i M of H7 or lOOnM of Ro 31-8220 for 30 min at 37°C and 
their effects on the basal level of cGMP production in C6 glioma 
cells monitored. These concentrations of PKC inhibitors were 
chosen as they had been shown to effectively inhibit PKC activity 
(Tamaoki et al” 1986; Hidaka and Hagiwara, 1987; Davis et al" 
1992). Also, these inhibitors inhibit different isoforms of PKC 
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Fig. 3.9: The effects of PKC inhibitors on cGMP production in 
C6 cells. Cells were equilibrated wi th SDMEM for 10 min and 
incubated w i th lOOnM ST, 1|LLM H7, or lOOnM Ro 31-8220 for 30 
m in at 37°C. cGMP level was measured as described before 
(Section 2.3). Values shown are means 土 SD of two experiments 
each in triplicate. 
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Fig. 3.9 showed the cGMP production in C6 cells incubated 
w i th different PKC inhibitors. The cGMP levels in cells incubated 
w i th ST (0.8 土 0.01 pmol /mg of protein), H7 (1.0 士 0.4 pmol /mg of 
protein) and Ro 31-8220 (0.7 士 0.1 pmol /mg of protein) were very 
similar to the basal level (0.8 土 0.1 pmol /mg of protein). Therefore, 
none of the three PKC inhibitors used in this experiment affected 
the basal cGMP production in C6 cells. 
3.1.4.2 Effects of PKC inhibitors on CNP-induced 
cGMP formation 
In this study, C6 cells were preincubated w i th one of the 
three PKC inhibitors in the same manner as previously described, 
and then w i th lOnM of CNP for another 10 min. 
Fig. 3.10 showed the cGMP production in C6 cells in the 
presence of lOnM of CNP wi th or without PKC inhibitors. In the 
presence of lOnM of CNP, cGMP formed was 21.3 士 3.1 pmol /mg 
of protein. A slight, but insignificant, decrease in CNP-stimulated 
cGMP production was observed in the presence of each of the 
PKC inhibitors. Cells treated w i th H7 showed the greatest 
decrease in CNP-induced cGMP formation, from 21.3 士 3.1 to 17.0 
土 3.3 pmo l /mg of protein, which was only 20%. However, none of 
the three inhibitors tested decreased CNP-induced cGMP 
formation significantly. Thus, it seemed that ST, H7 and Ro 31-
8220 did not interfere wi th the CNP-induced cGMP production in 
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Fig. 3.10: Effects of PKC inhibitors on CNP-induced cGMP 
production in C6 cells. Cells were equilibrated wi th SDMEM for 
10 min and preincubated wi th lOOnM ST, l | i M H7, or lOOnM Ro 
31-8220 for 30 min at 37°C, then exposed to lOnM CNP for 10 min. 
Cells incubated wi th CNP alone served as the control. cGMP level 
was measured as described before (Section 2.3). Values shown are 
means 土 SD of three experiments each in triplicate. 
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3.1.4.3 Antagonism of PKC inhibitors on the 
action of PMA on CNP-induced cGMP 
formation 
In previous experiments, it was shown that PMA (100 nM) 
could attenuate the CNP-induced cGMP responses in C6 glioma 
cells. As PMA is a potent PKC activator and its effect is mediated 
by the activation of PKC, and in order to confirm the inhibitory 
effect of PMA on CNP-induced cGMP formation was linked to 
PKC activation, three PKC inhibitors, ST, H7, and Ro 31-8220 
were employed to test if the inhibitory effect of PMA on CNP-
induced cGMP formation could be reversed by these PKC 
inhibitors. 
In these experiments, C6 glioma cells were preincubated 
w i th ST, H7 or Ro 31-8220 in various concentrations (suggested 
by project co-workers of the Dept. of Medicine, CUHK) as shown 
in Fig. 3.11 for 30 min at 37。C before exposure to lOOnM of PMA 
for 20 min. Incubation was continued for another 10 min in the 
presence of lOnM of CNP. 
Fig. 3.11 showed the effects of each of the three PKC 
inhibitors on PMA-reduced CNP-dependent cGMP formation. 
PMA (lOOnM) signif icantly reduced the cGMP formation 
stimulated by CNP (lOnM) from 22.7 土 4.5 pmol /mg of protein to 
9.0 土0.8 pmol /mg of protein. Among the three inhibitors tested, ST 
did not reverse the inhibitory effect of PMA, and the amount of 
cGMP formed was 10.9 土 4.5 pmol /mg of protein, which was not 
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Fig. 3.11: The antagonistic effects of PKC inhibitors on the 
action of PMA on CNP-induced cGMP production in C6 cells. 
Cells were equi l ibrated w i t h SDMEM for 10 min and 
preincubated wi th lOOnM ST, l|nM H7, or lOOnM Ro 31-8220 for 
30 min at 37°C. Then, lOOnM PMA was added and incubated for 
another 20 min before the exposure to lOnM CNP for 10 min. 
Cells incubated wi th CNP alone served as the control. cGMP level 
was measured as described before (Section 2.3). Values shown are 
means 土 SD of three experiments each in triplicate. * p<0.05, 
significantly different from the control by using Student's t -test. 
N.S., not significantly different. 
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significantly different from that w i th PMA treatment (9.0 ±0.8 
pmol /mg of protein). 
H7, another PKC inhibitor, which has been shown to inhibit 
some or all of the effects elicited by PKC activation (Hidaka and 
Hagiwara, 1987). However, H7, like ST, d id not significantly 
reverse the inhibitory action of PMA on CNP-induced cGMP 
production. It appeared that both ST and H7 were not able to 
reverse the effect of PMA on the CNP-dependent cGMP 
formation. In view of the reports that ST and H7 may not be 
selective enough to inhibit the PKC activity (Tamaoki et al, 1986; 
Huang, 1989), another PKC inhibitor, Ro 31-8220, which is 
reported to be more selective than the former two PKC inhibitors 
(Davis et al., 1992), was tested. 
As observed in Fig. 3.11, Ro 31-8220 reversed the inhibitory 
action of PMA on CNP-induced cGMP formation. Pre-exposure 
of cells to lOOnM of Ro 31-8220 reversed the level of cGMP from 
9.0 土 0.8 pmo l /mg of protein in the presence of PMA plus CNP to 
19.2 土 2.1 pmo l /mg of protein, which was similar to the cGMP 
level observed in the CNP-stimulated cells (22.7 士 4.5 pmol/mg). 
This f inding suggests that PKC activation was involved in 
mediating the inhibitory effect of PMA on CNP-dependent cGMP 
production in C6 cells. 
3.1.4.4 Antagonism of PKC inhibitors on the 




Since ET-3 was reported to be a potent PKC activator in 
other tissues (Simonson and Dunn, 1990; Masaki, 1991; 
Gr iend l ing et al” 1989), it is possible that the effect of ET-3 on 
CNP-induced cGMP formation in the C6 glioma cells may be 
mediated through PKC activation. If this is true, one would expect 
that the ET-3 inhibition on CNP-induced cGMP formation should 
be reversed by pre-exposure to one of these PKC inhibitors. As 
different PKC inhibitors showed different potencies in different 
cell types, three PKC inhibitors were used in this study, and they 
were ST, H7 and Ro 31-8220. 
In this study, C6 glioma cells were preincubated with ST, H7 
or Ro 31-8220, in the same concentrations as used in previous 
experiments, for 30 min at 37°C before exposure to lOOnM of ET-
3 for another 20 min, and then further incubated for 10 min in the 
presence of lOnM of CNP. 
As shown in Fig. 3.12, ET-3 reduced CNP-induced cGMP 
production by 85% (from 22.7 土 4.5 pmol /mg of protein to 3.4 土 0.7 
pmo l /mg of protein) in C6 glioma cells. Pre-exposure of the cells 
to one of the three PKC inhibitors significantly reversed the 
inhibitory effect of ET-3 on CNP-stimulated cGMP formation. In 
cells pre-treated w i th ST (lOOnM), H 7 (1|LIM) or Ro 31 -8220 
(lOOnM) fol lowed by ET-3 (lOOnM), the CNP-induced cGMP 
production were 6.4 土 1.6 pmol /mg of protein, 5.8 土 0.7 pmol /mg 
of protein and 11.5 士 1.3 pmol /mg of protein, respectively. It was 
clear that Ro 31-8220 had the greatest antagonistic effect on the 
ET-3 inhibition on CNP-induced cGMP formation, from 3.4 土 0.7 
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Fig. 3.12: The antagonistic effects of PKC inhibitors on the 
action of ET-3 on CNP-induced cGMP production in C6 cells. 
Cells were equi l ibrated w i t h SDMEM for 10 min and 
preincubated w i th lOOnM ST, l\iM H7, or lOOnM Ro 31-8220 for 
30 min at 37°C. Then, 100 n M ET-3 was added and incubated for 
another 20 min before the exposure to lOnM CNP for 10 min. 
Cells incubated wi th CNP alone served as the control. cGMP level 
was measured as described before (Section 2.3). Values shown are 
means 土 SD of three experiments each in triplicate. * p<0.05, 
significant difference from the control by using Student's t -test, 
料 p<0.05, significantly different from the treatment wi th ET-3 




effects of the other two PKC inhibitors were very slight and quite 
similar. ST and H7, which had no significant effect in reversing 
the inhibitory effect of PMA on CNP-induced cGMP formation in 
previous experiments, partially reverse the inhibitory effect of 
ET-3, i t is possible that these two PKC inhibitors exert their 
actions on some other protein kinases in the C6 glioma cells as 
these two inhibitors were not very selective (Tamaoki et al., 1986; 
Huang, 1989). Al though Ro 31-8220 was more effective in 
reversing the inhibitory action of ET-3. It d id not completely 
reversed the inhibitory action of ET-3-reduced on CNP-induced 
cGMP formation. The level of cGMP formed was only 11.5 ± 1.3 
pmol /mg of protein compared wi th 22.7 土 4.5 pmol /mg of protein 
in the presence of CNP alone. This f inding suggests that some 
unknown pathway other than PKC activation could be involved in 
mediating the effect of ET-3 to attenuate the CNP-induced cGMP 
formation in C6 cells. 
3.1.5 Effect of arachidonic acid on CNP-induced cGMP 
production in C6 glioma cells 
Since it was observed that ET-3 could activate PLA2 in some 
cell types (Ritz et al., 1992; Simonson and Dunn, 1990), the effect 
of arachidonic acid, an intermediate metabolite synthesized by 
PLA2, on CNP-stimulated cGMP formation was studied to 
investigate if PLA2 activation may be involved in mediating the 




In order to study the possible involvement of PLA2 
activation on CNP-induced cGMP formation, C6 glioma cells 
were preincubated w i th l\iM of arachidonic acid for 30 min at 
37°C, fol lowed by incubation wi th 10 nM of CNP for another 10 
min. l | i M of arachidonic acid was chosen as this is slightly higher 
than the concentration of free arachidonic acid found in most 
cells. 
As shown in Fig. 3.13, the cGMP levels in cells treated with 
lOnM of CNP (17.0 士 3.3 pmo l /mg of protein) and in those 
preincubated wi th arachidonic acid ( l | iM) before exposed to CNP 
(22.0 土 7.4 pmo l /mg of protein) were not significantly different. 
Thus, arachidonic acid d id not affect the CNP-induced cGMP 
formation and suggesting that PLA2 activation might not be 
involved in mediating the effect of ET-3 in attenuating the CNP-
induced cGMP formation. 
3.2 Effects of CNP and ET-3 on cellular metabolism in cultured 
rat C6 glioma cells 
As previous studies showed that PKC and PLA2 activation 
played only a relatively minor role in mediating the inhibitory 
action of ET-3 on CNP- induced cGMP formation, some other 
intracellular effects of CNP and ET-3 in the C6 glioma cells were 
examined. First, since ET-3 could raise intracellular Ca2 + levels 
(Goldman et al., 1991), the effects of CNP and ET-3 on calcium 
uptake were examined to investigate if these two peptides affect 
calcium uptake differently. Second, as both CNP and ET-3 
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Fig. 3.13: The effect of arachidonic acid on CNP-induced cGMP 
production in C6 cells. Cells were equilibrated wi th SDMEM for 
10 min and preincubated wi th l | i M arachidonic acid for 30 min at 
37°C before the exposure to lOnM CNP for another 10 min. 
cGMP level was measured as described before (Section 2.3). 




osmoregulating effects were tested by studying the effects of the 
two peptides on cell volume changes. Third, the possible effects of 
CNP and ET-3 on different transport systems in C6 cells were also 
examined. For example, the uptake of amino acids: taurine, 
glutamate, tyrosine and leucine, as well as glucose were carried 
out. Taurine is an osmoregulator in the brain and may be 
responsible for cell volume regulation in astrocytes (Pasantes-
Morales and Schousboe, 1990) while the others are well-known 
substrates of neural tissue metabolism. Taurine exists in high 
concentrations in the CNS and is transported by the p-amino 
acids transport system. In the CNS, glutamate is an excitatory 
amino acid and is taken up by astrocytes and stored in the form of 
glutamine (Hertz and Schousboe, 1986). In addition, controlling 
extracellular glutamate concentration is a function of astrocytes 
because high concentrations of glutamate are neurotoxic to 
neurons besides causing astrocytic swelling. Tyrosine, an 
aromatic amino acid and a precursor of dopamine and 
norepinephrine biosynthesis, is taken up through the aromatic 
amino acid system. Uptake of leucine, which occurs through an 
exchange system, serves mainly the nutritional requirements. The 
uptake processes for taurine, glutamate and tyrosine are Na+ -
dependent (Hosli et al； 1986); the uptake of leucine is via an 
exchange process (Oxender, 1972) and both the uptake of leucine 
and glucose are not Na+-dependent processes. Thus, these studies 
should shed light on the specific action, if any, of CNP and ET-3 
on different transport processes. Fourth, the effects of CNP and 




3.2.1 Effects of CNP and ET-3 on calcium uptake in C6 
glioma cells 
To study the effects of CNP and ET-3 on calcium uptake in 
C6 glioma cells, the cells were preincubated without peptide or 
w i th 10 n M or 100 n M of CNP or ET-3, or wi th both peptides, for 
20 min at 37 C in 0.25 ml of MCDB medium (0.03mM C a 2 + ) , then 
incubated in 0.25 ml of MCDB containing 45ca2+ (5|LiCi/ml) for 5 
min at 37 C. 
It has been reported that ET-3 at lOOnM was able to raise 
intracellular concentration in rat astrocytes (Goldman et 
al., 1991). In the present study, the results obtained appeared to 
agree w i th this report. As shown in Fig. 3.14, cells treated wi th 
lOOnM of ET-3 showed a 28% increase in uptake when 
compared wi th the control, but lOnM of ET-3 had no significant 
effect. Thus, i t seemed that ET-3 increased intracellular 
concentration of C a 2 + , at least in part, by increasing the uptake of 
C a 2 + . 
On the other hand, lOnM of CNP did not affect the uptake 
of Ca2+, while lOOnM of CNP was found to reduce the Ca2 + 
uptake by 43% compared wi th the control (without CNP addition) 
(Fig. 3.15). These apparently opposite effects of CNP and ET-3 on 
calcium uptake impl ied that these two peptides regulate 
intracellular Ca2 + level possibly by affecting the calcium uptake in 
C6 cells. 
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Fig. 3.14: The effect of ET-3 on calcium uptake in C6 cells. Cells 
were preincubated, in the absence, or wi th lOnM, or lOOnM ET-3 
for 20 m in at 37°C in 0.25ml of MCDB medium containing 
0.03mM Ca2 + , then incubated for another 5 min in 0.25ml MCDB 
containing 45ca2+ (5|xCi/ml). The medium in each well was 
discarded and the cells were washed wi th 2 x l m l of ice-cold 
physiological buffer (composition as described in Section 2.7) 
before solubilized wi th 1M NaOH. The radioactivity and protein 
in each wel l were determined as described in the Methods 
(Section 2.7). Values shown are means 士 SD of three experiments 
each in quadruplicate. * p<0.05, significantly different from the 
control by using Student's t -test. 
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Fig. 3.15: The effect of CNP on calcium uptake in C6 cells. Cells 
were preincubated, in the absence, or wi th lOnM, or lOOnM CNP 
for 20 min at 37°C in 0.25ml of MCDB medium containing 
0.03mM Ca2 + , then incubated for another 5 min in 0.25ml MCDB 
containing 45〔a2+ (5|iCi/ml). The medium in each well was 
discarded and the cells were washed wi th 2 x l m l of ice-cold 
physiological buffer (composition as described in Section 2.7) 
before solubilized wi th 1M NaOH. The radioactivity and protein 
in each wel l were determined as described in the Methods 
(Section 2.7). Values shown are means 士 SD of three experiments 
each in quadruplicate. * p<0.05, significantly different from the 
control by using Student's t -test. 
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In order to examine the possible interactions between CNP 
and ET-3 on Ca2+ uptake, cells were incubated in the absence, 
presence or different combinations of these two peptides as 
indicated in Fig. 3.16. As described before, CNP at lOOnM 
inh ib i ted wh i le ET-3 at lOOnM st imulated Ca2+ uptake. 
However, the combined actions of these two peptides, w i th 
different concentrations used (as shown in Fig. 3.16), d id not 
affect Ca 2 + uptake in C6 cells. This might be due to an additive 
effect of these two peptides, which cancelled out their individual 
effects on uptake. 
3.2.2 Effects of CNP and ET-3 on cell volume changes in C6 
glioma cells 
30MG is a glucose analog that cannot be metabolized in the 
cells and have been used as cell volume markers (Kimelberg and 
Frangakis, 1985). This is because glucose just equilibrate itself 
between the extracellular and intracellular spaces. 
In these experiments, cells were preincubated w i th lOOnM 
of CNP, 200nM of ET-3, or both for 24 hrs at 37 C before they 
were incubated w i th 0.25ml of physiological buffer (composition 
as described in Section 2.7) containing [3H]-30MG ( l | iC i /we l l ; 
specific activity: 3.4Ci/mmol) without cold glucose for 10 min at 
37 C The study of 10|LIM of dbcGMP and lOOnM of PMA were 
also carried out, as increase in intracellular cGMP and PKC 
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Fig. 3.16: Effects of ET-3 and CNP on calcium uptake in C6 cells. 
Cells were preincubated wi th different combinations of ET-3 and 
CNP, as shown, for 20 min at 37。C, and then incubated for 5 min 
in 0.25ml of MCDB containing 45ca2+ (5|iCi/ml) at 37。C. Other 
procedures were the same as described before (Fig. 3.14 and 
Section 2.7). Values shown are means 土 SD of three experiments 
each in quadruplicate. * p<0.05, significantly different from the 
control by using Student's t -test. N.S., not significantly different. 
90 
Results 
In Fig. 3.17, it was shown that the cell volumes in cells 
treated w i th either CNP or ET-3 were not different from that of 
the control. However, the cells treated wi th both peptides showed 
a significant increase in cell volume by 92% compared wi th the 
control. In agreement w i th the results obtained wi th the addition 
of CNP or ET-3 alone, both dbcGMP and PMA did not affect the 
cell volumes. The mechanism whereby a combination of CNP 
(lOOnM) and ET-3 (200nM) increased cell volumes in C6 cells is 
unclear. 
3.2.3 Effects of CNP and ET-3 on glucose and amino acids 
uptake in C6 glioma cells 
To assay the effects of these two peptides on cellular 
transport systems in C6 glioma cells, cells were primed wi th 
lOOnM of CNP, 200nM of ET-3 or both peptides for 24 hrs at 37 C 
before they were incubated wi th various labelled amino acids or 
glucose for 40 min. As CNP and ET-3 increased cGMP formation 
and activated PKC, respectively, the effects of lO^M of dbcGMP 
and lOOnM of PMA were also tested. In all uptake studies, the 
cells were washed twice wi th 0.5ml ice-cold physiological buffer 
at the end of the incubation period, and this was followed by the 
addit ion of 0.2ml of ice-cold 7.5% TCA. Then, the labelled 
substrate taken up by the cells was determined. As the amount of 
labelled amino acids incorporated into proteins after 40 min of 
incubation was less than 1% of the total, which was very low 
(results not shown), i t was assumed that the amount of 
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Fig. 3.17: Effects of CNP, ET-3, and other agents on cell volume 
changes i n C6 cells. Confluent cells were preincubated wi th 
lOOnM CNP, 200nM ET-3, CNP (lOOnM) plus ET-3 (200nM), 
dbcGMP (10|LiM) or PMA (lOOnM) for 24 hrs at 37°C. Then, cells 
were incubated w i th [ 3 H]-30MG (l juCi/well , specific activity: 
3.4Ci/mmol) in 0.25ml physiological buffer (without glucose) for 
10 min at 37°C and the medium in each well was discarded. Cells 
were washed twice w i th ice-cold physiological buffer, then 
solubilized wi th 1M NaOH. The radioactivity and protein in each 
wel l were determined as described for calcium uptake (Fig. 3.14 
and Section 2.7). Values shown are means 士 SD of three 
experiments each in quadruplicate. *p<0.05, significantly 
different from the control by using Student's t -test. 
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As shown in Fig. 3.18, CNP (lOOnM), ET-3 (200nM), or 
combination of these two peptides as well as dbcGMP (10|iiM) and 
PMA (lOOnM) did not affect glucose uptake in C6 cells. 
Fig.3.19 showed the effects of these two peptides, dbcGMP 
and PMA on taurine uptake. It was clear that cells primed wi th 
ET-3 (200nM) or PMA (lOOnM) showed a reduction in taurine 
uptake, and the inhibit ion was about 34% in cells primed wi th ET-
3 and about 32% in the PMA pre-treated cells, while other 
treatments showed no significant effect on taurine uptake. 
Fig. 3.20 showed the glutamate uptake in C6 cells following 
various treatments as described above. Neither CNP (lOOnM) nor 
ET-3 (200nM) affected the glutamate uptake in C6 cells. 
However, PMA (100 nM) showed an approximately 32% increase 
(p<0.05) in glutamate uptake. Although, dbcGMP (10|iM) seemed 
to reduce glutamate uptake in C6 cells, but the effect was not 
statistically significant. 
Fig. 3.21 showed the uptake of tyrosine in C6 glioma cells 
after var ious treatments. Neither CNP (lOOnM) nor ET-3 
(200nM) affected the tyrosine uptake in C6 cells. However, the 
combination of CNP and ET-3 slightly increased the uptake of 
tyrosine by about 10%, whi le tyrosine uptake was reduced by 
dbcGMP (10|iM) by 18% in C6 cells. Other treatments had no 
effect on tyrosine uptake. 
Al though the uptake of taurine, glutamate and tyrosine are 
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Fig. 3.18: Effects of CNP, ET-3, and other agents on glucose 
uptake in C6 cells. Confluent cells were preincubated with lOOnM 
CNP, 200nM ET-3, CNP (lOOnM) plus ET-3 (200nM), dbcGMP 
(10|nM) or PMA (lOOnM) for 24 hrs at 37。C Then, cells were 
incubated w i th [ 3 H ] - 3 0 M G (0.5(iCi/well , specific activity: 
3.4Ci/mmol) at a f inal concentration of 0.3mM in 0.25ml 
physiological buffer for 40 min at 37°C. The medium in each well 
was discarded and the cells washed twice w i th ice-cold 
physiological buffer, then solubilized w i th 1M NaOH. The 
radioactivity and protein in each wel l were determined as 
described for calcium uptake (Fig. 3.14 and Section 2.7). Values 
shown are means 土 SD of three experiments each in 
quadruplicate. 
94 
“ — Results 
35 -J 
3 0 _ * p<0.05 
I ^ z ^ % i 
U ^ £ 
Fig. 3.19: Effects of CNP, ET-3, and other agents on taurine 
uptake in C6 cells. Confluent cells were preincubated with lOOnM 
CNP, 200nM ET-3, CNP (lOOnM) plus ET-3 (200nM), dbcGMP 
(10|iM) or PMA (lOOnM) for 24 hrs at 37。C Then, cells were 
incubated w i th [3H]-taurine (0.2|iCi/well, specific activity: 
28Ci /mmol) at a f inal concentration of 0.3mM in 0.25ml of 
physiological buffer for 40 min at 37°C. Other procedures were 
the same as described in the Methods (Section 2.9.2). Values 
shown are means 土 SD of three experiments each in 
quadruplicate. . p<0.05, significantly different from the control by 
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Fig. 3.20: Effects of CNP, ET-3, and other agents on glutamate 
uptake in C6 cells. Confluent cells were preincubated with lOOnM 
CNP, 200nM ET-3, CNP (lOOnM) plus ET-3 (200nM), dbcGMP 
(10|LIM) or PMA (lOOnM) for 24 hrs at 37°C. Then, cells were 
incubated w i th [3H]-glutamate (0.2|iCi/well, specific activity: 
46Ci/mmol) at a f inal concentration of 0.3mM in 0.25ml of 
physiological buffer for 40 min at 37°C. Other procedures were 
the same as described in the Methods (Section 2.9.2). Values 
shown are means 土 SD of three experiments each in 
quadruplicate. * p<0.05, significantly different from the control by-
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Fig. 3.21: Effects of CNP, ET-3, and other agents on tyrosine 
uptake in C6 cells. Confluent cells were preincubated with lOOnM 
CNP, 200 n M ET-3, CNP (lOOnM) plus ET-3 (200nM), dbcGMP 
(10|iM) or PMA (lOOnM) for 24 hrs at 37。C Then, cells were 
incubated w i th [3H]-tyrosine (0.2(iCi/well, specific activity: 
45Ci/mmol) at a f inal concentration of 0.3mM in 0.25ml of 
physiological buffer for 40 min at 37°C. Other procedures were 
the same as described in the Methods (Section 2.9.2). Values 
shown are means 土 SD of three experiments each in 
quadruplicate. * p<0.05, significantly different from the control by 
using Student's t -test. 
97 
Results 
effects on these three transport systems. ET-3 alone decreased 
taurine uptake, but i t stimulated the uptake of tyrosine in the 
presence of CNP. However, these two peptides, either alone or in 
combination, d id not affect glutamate transport. On the other 
hand, PMA, as a PKC activator, decreased taurine uptake as ET-3 
did, but i t stimulated glutamate uptake. The effect of dbcGMP 
was very small and was only observed in tyrosine transport and 
this may be due to the low concentration of this nucleotide used. 
It seemed that the effects of CNP and ET-3 on substrate 
transport depended on the substrate studied rather than the Na+-
dependence of the transport system. 
Leucine is transported, i n many cells, via an exchange 
system. It was clear that PMA at lOOnM was the only agent tested 
that significantly increased the leucine uptake by approximately 
32% (p<0.05). On the other hand, CNP and dbcGMP seemed to 
reduce the leucine uptake by 15% and 18%, respectively, but were 
both not significant (Fig. 3.22). 
3.2.4 Effects of CNP and ET-3 on C6 cell proliferation 
To study the cell proliferation effects of CNP and ET-3, cells 
were pr imed w i t h lOOnM of CNP, 200nM of ET-3, IO^IM of 
dbcGMP, lOOnM of P M A , or 10|LIM of dbcAMP for 24 hrs at 37°C. 
Then, cells were pulsed wi th 2| iCi/wel l of [3H]-thymidine for 6 hrs 
and cell proliferation monitored by determining [3H]-thymidine 
incorporated into D N A (Fig. 3.23). 
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Fig. 3.22: Effects of CNP, ET-3, and other agents on leucine 
uptake in C6 cells. Confluent cells were preincubated with lOOnM 
CNP, 200nM ET-3, CNP (lOOnM) plus ET-3 (200nM), dbcGMP 
(10|iM) or PMA (lOOnM) for 24 hrs at 37。C. Then, cells were 
incubated w i t h [3H]-leucine (0.2|iCi/well, specific activity: 
164Ci/mmol) at a f inal concentration of 0.3mM in 0.25ml of 
physiological buffer for 40 min at 37。C. Other procedures were 
the same as described in the Methods (Section 2.9.2). Values 
shown are means 土 SD of three experiments each in 
quadruplicate. * p<0.05, significantly different from the control by 
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Fig. 3.23: Effects of CNP and ET-3 on thymidine incorporation 
in C6 cells. Cells were primed with CNP (lOOnM), ET-3 (200nM), 
dbcGMP (10^M), PMA (lOOnM), or dbcAMP ( 1 0 _ ) , as shown, 
for 24 hrs at 37°C. The cells were then pulsed wi th [3H]-thymidine 
(0.5 j iCi /wel l ) for 6 hrs at 37°C before harvesting. Values shown 
are means 士 SD of three experiments each w i th six separate 
determinations. * p<0.05, significantly different from the control 
by using Student's t -test. 
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[3H]-thymidine incorporation was found to be highest in the 
cells pr imed w i t h cGMP, which showed an 125% increase 
(p<0.05). The second highest thymidine incorporation was 
observed in cells pr imed w i th PMA, which produced a 86% 
increase of incorporation (p<0.05). ET-3 and dbcAMP also 
showed significant increase in [3H]-thymidine incorporation in C6 
cells, w i th an increase of 59% and 50% (p<0.05), respectively. 
The stimulatory actions of ET-3 and PMA on [3H]-thymidine 
incorporation in C6 cells were expected as both activate PKC and 
that st imulat ion of PKC had been shown to cause cell 
proliferation in several cell types (Simonson and Dunn, 1990; 
Masaki, 1991). Since both dbcGMP and dbcAMP were reported to 
have moderate anti-proliferative effects on some cell types 
including astrocytes (Appel, 1992; Levin and Frank, 1991), the 
stimulation shown by these two cyclic nucleotides on P H ] -
thymidine incorporation in C6 cells was unclear. 
3.2.5 Effects of CNP and ET-3 on RNA synthesis 
In this study, the priming conditions of C6 cells were the 
same as described for [3H]-thymidine incorporation. Briefly, cells 
were pulsed w i th 2| iCi /wel l of [3H]-nridine for 6hrs and RNA 
synthesis monitored by determining [3H]-uridine incorporated 
into RNA. 
Fig. 3.24 showed that only ET-3 and PMA stimulated [3H]-
uridine incorporation, and they increased the incorporation by 
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Fig. 3.24: Effects of CNP and ET-3 on uridine incorporation in 
C6 cells. Cells were primed wi th CNP (lOOnM), ET-3 (200nM), 
dbcGMP (10|iM), PMA (lOOnM), or dbcAMP (10|iM), as shown, 
for 24 hrs at 37°C. The cells were then pulsed wi th [3H]-uridine 
(0.5|iCi/well) for 6 hrs at 37°C before harvesting. Values shown 
are means 士 SD of three experiments each wi th six separate 
determinations. * p<0.05, significantly different from the control 
by using Student's t -test. 
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42% and 48% (p<0.05 in both cases), respectively. Other 
treatments had no effect on [3H]-uridine incorporation. 
3.2.6 Effects of CNP and ET-3 on protein synthesis 
[3H]-leucine was used to assess protein synthesis because 
leucine is a ketogenic amino acid and is not metabolised to a great 
extent in most cells. In this study, the priming conditions of C6 
cells were the same as described for [ 3 H ] - t h y m i d i n e 
incorporation. In this study, C6 cells were incubated wi th [ 3H]-
leucine for 6 hrs, and the radioactivity in the TCA precipitate was 
measured to assess [^HJ-leucine incorporation. 
Fig. 3.25 showed the results of [3H]-leucine incorporation in 
C6 cells. Similar to the findings in the [^HJ-uridine incorporation 
study, ET-3 and PMA stimulated [^HJ-leucine incorporation by 
21% and 32% (p<0.05 in both cases), respectively. Also, dbcGMP 
increased [3H]-leucine incorporation by 29% (p<0.05). 
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Fig.3.25: Effects of CNP and ET-3 on leucine incorporation in 
C6 cells. Cells were primed wi th CNP (lOOnM), ET-3 (200nM), 
dbcGMP (10|iM), PMA (lOOnM), or dbcAMP (lOjiM), as shown, 
for 24 hrs at 37°C. The cells were then pulsed wi th [3H]-leucine 
(0.5|iCi/well) for 6 hrs at 37。C before harvesting. Values shown 
are means 土 SD of three experiments each w i th six separate 
determinations. * p<0.05, sigriificantly different from the control 
by using Student's t -test. 
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Chapter 4 Discussion and Conclusion 
Both NPs and ETs are hormones involved in the regulation 
of systemic fluid and electrolyte metabolism. They have opposite 
biological actions in the vascular system as well as water and 
electrolyte excretion (Marin-Grez et d., 1986; Yanagisawa et al, 
1988a,b; Badr et al.f 1989; Kohno et al； 1993). There is increasing 
evidence that many bioactive peptides that were first discovered 
in peripheral organs, are often present in the CNS. In the cases of 
NP and ET, CNP and ET-3, respectively, are the predominant 
forms existing in the CNS. However, their actions in the CNS 
and the relationship, if any, between their central and peripheral 
effects are largely unknown. 
Although both CNP and ET-3 were found in the brain and 
the existence of specific binding sites for each of them are 
localized in the CNS, particularly in the astrocytes, little is known 
about their biochemical and physiological actions in the brain at 
present. Recent evidence suggested that CNP and ET-3 might 
interact w i th in the CNS to regulate f lu id and electrolyte 
metabolism (Sudoh et al, 1990; Samson et al； 1991c). Moreover, 
it was demonstrated recently that CNP was a potent stimulator of 
cGMP production in mouse astrocyte cultures (Yeung et.al” 
1992a), and ET-3 was involved in the secretion of several 
hormones from the pituitary glands (Samson et al., 1991b,c). In 
view of the fact that specific binding sites for these two peptides 
are found in astrocytes (Yeung et al" 1991b, 1992a; MacCumber et 
al； 1990), cGMP production was selected as a parameter to study 
the possible interactions between CNP and ET-3 at the second 
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messengers level in C6 glioma cells. We believe that this study 
should provide some information on how these two peptides 
exerted their central actions. The major aims of this study are to 
examine the effects of CNP and ET-3 on cGMP production in rat 
C6 glioma cells and to elucidate their possible effects on other 
cellular metabolic processes. Rat C6 glioma cells were employed 
in this project because they contain nearly all characteristics of 
glial cells and are easily available in large cell number due to their 
rapid growth. Also, their malignant properties would enable the 
findings obtained to compare wi th those in primary cultures. The 
effects of CNP and ET-3 demonstrated in the C6 cells could then 
provide a better understanding on their actions in the brain, which 
w i l l provide a more solid basis for further studies on their 
mechanisms of action as well as the relationship between their 
central and peripheral effects. 
In the present study, the effects of CNP and ET-3 on cGMP 
production were first examined by establishing the time course 
and dose dependency of CNP on cGMP production in C6 glioma 
cells, and then the effects of various concentrations and time of 
exposure of ET-3 on CNP-induced cGMP formation investigated. 
In addition, several cellular metabolic processes were examined in 
order to identify the intracellular mechanisms that mediated the 
actions of ET-3 on CNP-induced cGMP formation. These included 
the effect of PMA, a PKC activator, since ET-3 has been shown to 
activate the PKC (Simonson and Dunn, 1990; Masaki, 1991; 
Griendling et al, 1989); and also the action of arachidonic acid, 
because the PLA2 pathway was involved in the action of ET-3 in 
some cell types (Ritz et al, 1992; Simonson and Dunn, 1990; 
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Masaki, 1991; Thomas et al” 1991; Resink et al” 1989). Since ET-3 
can increase intracellular calcium level, the effects of CNP and 
ET-3 on calcium uptake were studied to investigate the possible 
interaction between these two peptides in calcium transport 
mechanism as wel l as intracellular calcium regulation. As both 
peptides are involved in fluid and electrolytes regulation in the 
periphery, their possible osmoregulating effects on C6 cells were 
tested to obtain some insights in their effects on cell volumes. 
Change in cell volume in astrocytes is one of the biological 
responses often observed in brain injury (Kimelberg and Ransom, 
1986). Besides, the effects of CNP and ET-3 on various transport 
systems, such as amino acids and glucose, as wel l as on DNA, 
RNA and protein synthesis were also examined. These were 
carried out to see if these two peptides would affect these 
metabolic processes differently as ET and NP have been shown to 
.have mitogenic effects and antimitogenic effects, respectively 
(MacCumber et al., 1990; Appel, 1992). 
The results showed that cGMP production in C6 glioma 
cells was markedly stimulated by CNP in time-dependent (Fig. 
3.1) and dose-dependent (Fig. 3.2) manners. Just 10 min exposure 
to lOnM of CNP was found to be adequate to produce the optimal 
effect of CNP on cGMP production. The EC50 of CNP on cGMP 
production was found to be 17nM. Although the EC50 obtained 
w i th C6 glioma cells was lower than that obtained wi th mouse 
astrocytes (EC50 = 32nM) (Yeung et al； 1992a), the maximal 
st imulatory effect of CNP on cGMP production in mouse 
astrocytes was 196.2 土 22.0 pmol /mg of protein which was 12-fold 
greater than that observed in C6 glioma cells. These indicated 
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that CNP was more effective in normal astrocytes than in this 
malignant cell type. While many factors might affect the 
differential effects of CNP in these two cell types, one of the 
plausible explanation may be due to a lower expression of specific 
receptors (ANPR-B) for CNP in the glioma cells. This possibility 
should be examined in future studies. 
The cGMP production stimulated by CNP was inhibited by 
ET-3, a potent vasoconstrictor in the peripheral systems which 
has recently been found to be synthesized by and binds specifically 
to ET receptors in astrocytes. Attenuation of CNP-stimulated 
cGMP formation by ET-3 in C6 glioma cells was time-dependent 
(Fig. 3.4), and maximum inhibition was achieved wi th 20 min of 
preincubation. Besides, ET-3 suppressed cGMP production in 
response to lOnM CNP was found to be dose-dependent (Fig. 3.5), 
w i th an IC50 of 1.4nM. The maximum inhibition was observed 
w i th 2 | iM of ET-3, at this concentration a 76% reduction of the 
CNP-induced cGMP formation was observed. This effect of ET-3 
on CNP-induced cGMP production in C6 cells provides a direct 
support to the notion that CNP and ET-3 have opposite actions in 
the CNS similar to those in the peripheral systems. 
ET-3 is a known PKC stimulator (Simonson and Dunn, 1990; 
Masaki, 1991; Griendling et al, 1989), and that the PKC family of 
enzymes are particularly abundant in the CNS (Kikkawa et al” 
1989). Thus, i t is natural to investigate the roles of PKC on cGMP 
formation. In addition, PKC are known to play roles in various 
important cellular processes, such as, ion conductance, cell 
prol i feration and cell differentiation (Kikkawa et al, 1989). 
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Moreover, distinct isoforms of PKC have recently been identified 
in different types of glial cells and may mediate various functions 
wi th in these cells (Masliah et al., 1991); therefore, the possible 
role of PKC and CNP-dependent cGMP formation was examined 
in the C 6 glioma cells. In this study, phorbol ester PMA, a potent 
PKC activator (Stassen et al” 1989), was first used to test the 
effects of PKC on CNP-dependent cGMP formation. The results 
indicated that the cGMP production stimulated by CNP was 
suppressed by PMA in time- and dose-dependent fashion (Figs. 
3.7 and 3.8), w i th an IC50 value of 2nM. Maximum inhibitory 
concentration of PMA was found to be 10|LIM; at this 
concentration of PMA a 70% reduction of the cGMP formation 
induced by lOnM of CNP was observed. The effect of PMA was 
found to be more potent in C6 glioma cells (IC50 = 2nM) than in 
mouse astrocytes (IC50 = 6nM) (Yeung et al., 1992b). It is not clear 
whether this is due to the malignancy in nature of the C6 cells. In 
l ine w i t h this f ind ing is that some other PKC-activating 
hormones, such as A VP and Agll , also inhibit ANP-induced cGMP 
accumulation in astrocytes (Erusalimsky and Rozengurt, 1989; 
Chardonnens et al, 1989). Therefore, it' appears that some 
neuropeptides may interact w i th CNP in the CNS, at least 
partially, through modulation of PKC activity. 
The role of PKC activation in mediating the inhibitory effect 
on CNP-induced cGMP formation is supported by another 
observation, in which the inhibitory action of PMA was blocked by 
a PKC inhibitor, Ro 31-8220 but not by ST and H7 (Fig. 3.11). Ro 
31-8220 is a compound belongs to the series of 
bisindolylmaleimide PKC inhibitors that interact with the putative 
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amine or cation binding site in the enzyme (Davis et al, 1992). 
This PKC inhibitor was reported to have greater potency and 
higher selectivity than the parent bisindolylmaleimide compound 
and the natural product staurosporine (ST) (Davis et al” 1992). In 
fact, ST and another PKC inhibitor, H7, were also examined to 
see if they could reverse the action of PMA, but both of them were 
not effective in the present study. Both H7 and ST have been 
identified to exert their actions by interfering wi th the interaction 
of ATP and protein substrate wi th the catalytic domain of PKC. 
H7 inhibits PKC by competition wi th ATP (Hidaka and Hagiwara, 
1987). Since the structure of the ATP-binding sites for all protein 
kinases are highly conserved, H7 is also effective on other protein 
kinases (Huang, 1989). On the other hand, ST is a more potent 
PKC inhibitor, but also inhibits the cAMP-dependent protein 
kinase (PICA) (Tamaoki et al, 1986). Thus, the low selectivity of 
these two PKC inhibitors to inhibit PKC specifically could account 
for their inability to reverse the action of PMA. Since it is known 
that CNP acts upon an isoform of receptor guanylate cyclase 
(GC-B) (Koller et al” 1991), the attenuation of the CNP-induced 
cGMP response by PKC could be mediated by phosphorylation of 
receptor GC-B, which in turn leads to a decrease in CNP binding 
and/or suppression of the activity of the kinase-like or catalytic 
domain. This possibility should be considered in future studies. 
Compared wi th the effect of ET-3, PMA was less potent and 
effective (Figs. 3.5 and 3.8). Moreover, the cGMP production in 
C6 glioma cells in response to lOnM CNP was attenuated but not 
ful ly blocked, even wi th high doses of PMA. Also, even Ro 31-8220, 
which showed a nearly complete antagonism on the action of 
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PMA, could only partially reverse the inhibitory action of ET-3 on 
CNP-stimulated cGMP formation (Fig. 3.12). These results 
suggest that some unknown pathways, in addit ion to PKC 
activation, could also be involved to mediate the ET-3-induced 
attenuation on the cGMP production stimulated by CNP, The 
mechanism is unclear at present. 
ET has been reported to activate phospholipases, such as 
P L A 2 , in several cell types (Ritz et al, 1992; Simonson and Dunn, 
1990; Masaki, 1991; Thomas et al； 1991; Resink et al., 1989). 
Moreover, in the neurohypophysis, ET-3 had been shown to 
enhance A VP secretion without increase in intracellular calcium 
level and that arachidonic acid produced by activated PLA2 can 
potentiate the A VP release in the absence of calcium (Ritz et al, 
1992). It is possible that arachidonic acid production may also be 
involved in mediating the effect of ET-3 on CNP-induced cGMP 
formation in the C6 glioma cells. In the present study, we took the 
simplest approach by incubating cells w i th arachidonic acid to 
investigate the effect of arachidonic acid on CNP-induced cGMP 
formation, but arachidonic acid d id not affect the cGMP 
formation stimulated by CNP (Fig. 3.13). It seems that arachidonic 
acid and thus PLA2 activation may not be involved in ET-3-
reduced CNP-stimulated cGMP formation. 
ET-3 has been shown to increase intracellular calcium level 
by two distinct pathways: IP3-induced Ca 2 + mobilization or 
receptor — operated Ca2+ inf lux in astrocytes (Goldman et al, 
1991； Chuang et alr 1991). In accordance wi th this, ET-3 at 100 
n M induced an increase in 45ca2+ uptake by 28% in the C6 glioma 
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cells (Fig. 3.14). On the other hand, 100 nM of CNP was found to 
reduce the 45ca2+ uptake significantly by 43% (Fig. 3.15). Similar 
reduction of intracellular Ca2+ level was also observed in smooth 
muscle cells as wel l as mesangial cells that treated wi th ANP 
(Levin and Frank, 1991; Appel et al., 1987). These results show that 
CNP and ET-3 have opposite actions in calcium transport in C6 
glioma cells, this thought was further supported by the finding 
that the combined treatment of CNP and ET-3 in C6 glioma cells 
d id not show significant changes in 45ca 2 + uptake (Fig. 3.16). 
Studies w i th higher concentrations of CNP (>100nM) and ET-3 
(>100nM) were not performed due to the fact that 
unphysiological doses of these peptides have to be used. From the 
results i t seems reasonable to postulate that CNP may interact 
w i th ET-3 in mediating transport and in turn regulate 
intracellular Ca2+ level in astrocytes. 
The 30MG uptake technique, which has been used as an 
index to monitor cell volume changes in astrocytes (Kimelberg 
and Frangakis, 1985), was adapted in this project to study the cell 
volume changes in C6 glioma cells treated w i th CNP and ET-3. 
This study is of particular interest since centrally released AVP and 
ANP have recently been shown to be physiological regulators of 
cell volumes in brain (Doczi, 1993) and that pituitary secretion of 
AVP is stimulated by ET-3 (Yamashita et al., 1991; Samson et al., 
1991c； Ritz et al； 1992; Rossi, 1993). It has been demonstrated that 
exogenous AVP increases the water content of the brain, 
facilitating oedema formation; on the other hand, ANP decreases 
the brain iori (e.g. Na+) and water contents. Moreover, AVP was 
f Q u n d to increase the glial cell volume whereas ANP decreased i t 
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(Doczi, 1993). However, our results showed that neither peptide 
alone affected C6 cell volumes (Fig. 3.17). It may be due to the fact 
that ANP and CNP bind to different central receptors (Koller et 
flZ., 1991). This observation may also be due to the different actions 
of ANP and CNP since CNP was found to stimulate while ANP 
reduced dr inking behavior in rats (Samson et al" 1991a). Thus, 
ANP and CNP may have different central actions. It had been 
reported that the volume response induced by A VP or ANP in brain 
cells was receptor-mediated and involved the Na+-K+-2C1" co-
transporter (Doczi, 1993); however, the mechanism related to the 
increase in cell volume in cells treated wi th both CNP and ET-3 is 
unclear (Fig. 3.17). Since these two peptides have differential 
effects on cGMP formation and calcium transport, and neither 
exogenous cGMP nor PMA affected the cell volumes of C6 glioma 
cells, i t is unlikely that cGMP, and PKC are involved in the 
effects of CNP and ET-3 on cell volume changes. 
The lack of effects of CNP and ET-3 on glucose uptake (Fig. 
3.18) was not surprising as both peptides are not related to energy 
metabolism. Among the Na+-dependent amino acids transport 
systems studied, i t was found that the actions of CNP and ET-3 
var ied according to the substrate investigated. ET-3 alone 
decreased taurine uptake (Fig. 3.19) but stimulated the uptake of 
tyrosine in the presence of CNP (Fig. 3.21), while neither peptide 
alone nor their combination affected the glutamate transport 
(Fig. 3.20). On the other hand, PMA decreased taurine uptake 
(Fig. 319)； as ET-3 did, but i t stimulated glutamate uptake (Fig. 
3.20), and exogenous cGMP decreased: the uptake of tyrosine (Fig. 
3.21). Since these amino acids are transported via Na+-dependent 
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systems, it is unlikely that CNP and ET-3 affected the transport of 
these amino acids by affecting Na+ transport, despite the fact that 
ANP, an analog of CNP, has been reported to reduce cell volume 
by acting on ion transporters (Doczi, 1993; Appel, 1992). In the 
case of leucine uptake, PMA was the only effective agent that 
stimulated leucine uptake (Fig. 3.22), and this may be related to 
the proliferative effects of the PKC system. 
The effects of CNP and ET-3 on amino acid transport 
appear to be substrate-dependent and is unrelated to cGMP 
formation or calcium transport as no correlation can be found. 
The stimulatory effects of ET-3 and PMA on DNA, RNA and 
protein synthesis as demonstrated in C6 glioma cells (Figs. 3.23, 
3.24 and 3.25) in the present study is consistent w i th the report 
that ET-3 was a mitogen in the C6 glioma cells (MacCumber et 
al., 1990) and that the mitogenic effect was believed to be 
mediated through PKC activation and N a + - H + antiport 
(Simonson and Dunn, 1990; Masaki, 1991). On the other hand, 
although CNP alone did not show antimitogenic effect (Figs. 3.23, 
3.24 and 3.25) in the C6 glioma cells as ANP and BNP did in rat 
astrocytes and in the peripheral tissues (Levin and Frank, 1991; 
Appel, 1992), i t inhibited the ET-3-stimulated incorporations of 
thymidine, uridine and leucine. This result indicates that CNP can 
inhibit the ET-3-induced mitogenic activity in the C6 glioma cells. 
This is similar to the effect of ANP on ET-1 observed in the 
mesangial cells (Sugimoto et al, 1993). I t is believed that the 
antimitogenic effect of the NP is not due to neurotoxic actions 
{Sugimoto et al； 1993). I t is possible that a cGMP-independent 
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mechanism elicited by the ANPR-C (the clearance receptor) is 
involved in the antimitogenic effects of CNP rather than the 
cGMP production elicited by ANPR-A or ANPR-B, as exogenous 
cGMP did not show antimitogenic effect in this study (Figs. 3.23, 
3.24 and 3.25) although very high concentration (lOmM) of cGMP 
had been shown to be antimitogenic (Appel, 1992). However, it is 
not known if ANPR-C is present in C6 cells. Another possibility is 
that the inhibition on the ET-3-induced mitogenesis by CNP was 
mediated via the Ca2+ transport systems as ET-3 stimulated 
Ca2+ uptake while CNP inhibited it in C6 glioma cells (Figs. 3.14 
and 3.15), also, increase in intracellular Ca2+ concentration is 
known to be mitogenic (Stull et al" 1986). In this study, exogenous 
cGMP not only showed no antimitogenic effect, in fact, it 
stimulated thymidine and leucine incorporation (Figs. 3.23 and 
3.25), which was unexpected and the reason was unclear. 
In conclusion, the present study has shown that CNP 
stimulated cGMP formation, while ET-3 reduced this stimulation 
in the C6 glioma cells. Also, ET-3 increased but CNP inhibited 
Ca2+ uptake. These results are consistent wi th the finding that 
NP and ET have opposite biological actions in peripheral systems. 
Moreover, the mitogenic activity induced by ET-3 was inhibited by 
CNP. These findings give support to the notion that CNP and ET-
3, being synthesized in the brain, may interact in the CNS to 
regulate the central actions of each other. Although ANP and ET-1 
have been reported to regulate fluid and electrolyte balance in 
peripheral systems, neither CNP nor ET-3 alone caused cell 
volume changes in C6 cells despite the fact that the presence of 
both peptides greatly increased cell volumes. It would appear that 
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these two peptides may not play a prominent role in fluid and 
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